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xSUMMARY
Biological systems experience changes in response to diseases or environmental
stressors and these changes are fundamentally driven by the molecular components
such as genes, proteins and metabolites. Metabolites are the chemical substances
transformed by enzymes as part of a complex metabolism network. This network is
further regulated by complex upstream cellular processes involving proteins and
genes. Since metabolites are the end-products of cellular activity, they represent the
downstream phenotypic response of the cellular regulation. Metabolomics, as
discussed in Chapter 1 of this thesis, is a high-throughput profiling platform that
simultaneously measures metabolites to provide information on dynamic responses
made by biological systems. Compared to typical hypothesis-driven studies, omics
studies are usually discovery-driven and exploratory in nature. Nevertheless, this
platform technology has been extensively used recently to study hypothesis-driven
research questions by revealing unique molecular insights of different diseases and
toxicological responses.
In this thesis, metabolomics was applied to in vitro, in vivo and human samples to
assess the applicability of this relatively new technology to different sample types
encountered in biomedical and environmental research. From cell lines to human
samples, these sample types exhibit increasing variability and complexity that poses
experimental design and analytical challenges. The sources of these samples are three
biological systems that include cultured human lung fibroblasts, zebrafish embryos
and human urine samples from the Singapore Diabetes Cohort Study (SDCS).
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Cell lines are biological systems that are well-controlled and genetically uniform.
Hence in the context of metabolomics, they are a sample type with low complexity
and high uniformity. Cell lines are often employed as a model system to evaluate
effects of compounds and in Chapter 2, we examined the feasibility of applying
metabolomics to nanoparticle-treated cell lines for improved detection of biological
effects. Briefly, human lung fibroblasts (MRC-5 cell line) were treated with nano-
sized silica (nanosilica) in increasing doses (control, 2.5, 10, 40, 80µg/mL) and
measured for cell viability and overt morphological changes. Nanosilica is a novel
particulate compound of less than 100nm in diameter and it represents a class of
nanoparticles that are of health concern. At this size, it may exhibit novel
physicochemical properties and we hypothesized that such properties may also induce
toxicity in cells that may not be normally detected using traditional approaches.
Despite initial observations of no significant effects in cell viability and morphology,
metabolomics was able to detect metabolic responses induced by nanosilica. Samples
of different dose treatments were well-classified using multivariate analysis and dose-
dependent alterations of amino acids, phospholipids and glutathione were observed.
Further investigations involving ultrastructural studies revealed uptake of nanosilica
through dose-dependently increased vacuolization. Here the feasibility of
metabolomics for in vitro investigations was demonstrated and metabolomics further
complemented existing methodologies for toxicological assessment.
In vivo animal models are valuable in demonstrating and extrapolating clinical
relevance of exposure and effects to humans. Consisting of multiple tissue types,
aquarium fish represents the next hierarchy of complexity and variability above cell
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lines. Zebrafish embryos are increasingly recognized as a viable alternative for
toxicological studies, much due to its genetic relevance to humans, in addition to
optical transparency, low cost of animal husbandry and strong potential for high-
throughput studies. The application of metabolomics to zebrafish embryos would
ideally bring forth improved detection of exposure effects through sensitive high-
throughput studies.  In order to first understand the basic physiology of zebrafish
embryos, the metabolic profiles occurring throughout the zebrafish embryonic
development (4, 8, 12, 24, 48 hours post fertilization (hpf)) were interrogated. As
elaborated in Chapter 3, the basic physiological information of zebrafish development
was crucial for optimizing the ideal time point for treatment duration and sampling.
Metabolic profiles were observed to be increasingly complex as development
progressed and the 48 hpf profile was found to be the most complex with the largest
number of detectable metabolites. This finding was further corroborated by
transcriptome data, where more mRNA transcripts were found upregulated in later
stages of development. The complexity of the 48 hpf profile further suggests that
more metabolic perturbation effects could be observed if exposure of embryos to
environmental stressors were sustained up till and beyond 48 hpf.
Based on the physiology and time point knowledge revealed by metabolomics, we
hypothesized that the zebrafish-metabolomics platform could be deployed as an in
vivo toxicology tool to understand metabolic perturbation caused by N-
nitrosodimethylamine (NDMA), a potent carcinogen present in drinking water. The
embryos were exposed to increasing doses of NDMA (0, 0.1, 1, 10 µg/L) with the
exposure sustained up to 48 hpf. Morphological inspection of zebrafish embryos and
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mortality counts revealed no significant effects of NDMA up to the highest dose of 10
µg/L of NDMA. Despite the lack of observable effects, it was observed that amino
acids, lipid-related metabolites and glutathione were significantly changed upon
increasing the dose of NDMA. As exemplified by this zebrafish-metabolomics
platform, novel insights can be generated from metabolomics to complement existing
toxicological knowledge.
Clinical samples are the most direct and relevant means of studying disease
mechanism and stressor effects. It is also however, one of the most variable and
complex biological specimens to study due to genetic and lifestyle differences within
the sample population. Urine is a biofluid generated by glomerular filtration of blood
and accompanying renal processes in the kidney. The filtered metabolites originate
from the whole organ system of the body and may be further influenced by varied
activities such as food intake, smoking and gender. These factors would therefore
rank urine as the most complex and variable sample type to analyse from the technical
aspect. In Chapter 4 we applied metabolomics to study the feasibility of urine
metabolomics owing to the benefits of non-invasive sampling and ease of collection
from the study population.
In the diagnosis of renal insufficiency, urine samples from patients are traditionally
analysed to assess renal function, notably via the detection of abnormal protein level
in urine. In order to find out whether a high-throughput metabolomic approach could
offer a better understanding on the disease mechanism and also identification of early
detection biomarkers, a study was thus carried out on a unique sub-population
amongst Type II diabetes mellitus patients that exhibits renal insufficiency despite
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lacking classical symptoms of proteinuria. We hypothesize that the use of
metabolomics could provide novel biomarkers suitable for early prevention of renal
insufficiency. Using urine samples collected from non-proteinuric diabetic patients
with and without low renal function, we demonstrated that patients with low renal
function were well-differentiated from the reference subjects based on their metabolic
profiles and a panel of biomarkers were further derived using Least Absolute
Shrinkage and Selection Operator (LASSO) logistic regression for discriminating
between cases and controls. Based on further validation, the biomarkers were found to
be robust for identifying non-proteinuric diabetic patients with renal insufficiency.
The results from these three studies consistently corroborated that metabolomics
demonstrates strong usability across various sample types for understanding
biological responses and biomarker discovery. Furthermore, these studies reaffirm
that metabolite levels are indeed a valuable source of information for understanding
diseases and toxicological responses.
Metabolomics is a rapidly-evolving discipline of systems biology, with major
advances in analytical chemistry and related bioinformatics.  However, the current
state of metabolomics analysis lacks a unified framework to better realise its potential
and broader usability. At present, many commercial or established software programs
are required to perform the diverse analytical processes underlying metabolomics.
The integration of these program outputs is non-trivial and inefficient with poor
amenability for optimization. In addition, the reproducibility of results may also be
compromised due to the lack of well-documented processing methods.
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Through the development of a streamlined and customizable software, referred to as
MetaboNexus, metabolomics investigations can be accelerated and optimized for
rapid statistical analysis and metabolite discovery.  As discussed in Chapter 5,
MetaboNexus consists of modules that perform raw data processing, statistical
analysis as well as metabolite identification capabilities. With a data log documenting
each analysis, the results can be made reproducible and accessible by collaborators
and broader readership.
The overall findings of this thesis demonstrate that metabolomics can complement
and add value to existing approaches in biomedical and environmental research by
providing a comprehensive and sensitive means of detecting and classifying
biological responses in sample types of increasing complexity. The development of an
integrated software further unifies essential tools to enhance the analytical process in
metabolomics. Limitations in the field of metabolomics pertaining to metabolite
identification, biological interpretation and scalability of experiments to large sample
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1.1.1 Metabolomics as a tool for understanding responses in biological systems
Biological systems undergo changes in response to diseases or environmental
stressors and these changes are fundamentally driven by the molecular components
such as genes, proteins and metabolites (Sauer, Heinemann, & Zamboni, 2007). Often,
the responses generate and/or modify a broad array of molecular components that are
interdependent and integrated with each other. For example, a transcription factor
would initiate the expression of a certain class of genes in response to a stressor and
the translation of these genes may further regulate other protein functions in the
complex regulatory network (Watson, MacNeil, Arda, Zhu, & Walhout, 2013). The
collective interplay of these relatively simple molecular components achieves
complex emergent properties such as the cellular ability to combat oxidative stress
(Finkel & Holbrook, 2000), increase energy production and proliferate (Vander
Heiden, Cantley, & Thompson, 2009). A graphical representation of how gene
expression and its downstream effects is described in Fig. 1.1.
Traditionally, researchers studying biological systems have adopted a reductionist
approach to understand their underlying molecular biology (Ahn, Tewari, Poon, &
Phillips, 2006a, 2006b; Fang & Casadevall, 2011). With the advent of high-
throughput profiling technology such as genomics (Venter et al., 2001) and
proteomics (Görg, Weiss, & Dunn, 2004; Schmidt, Kellermann, & Lottspeich, 2005),
it became feasible to explore the collective global changes that occur in a biological
system in response to diseases or environmental stressors.
3Fig. 1.1 Metabolomics studies the metabolites present in a biological sample and these
metabolites are end-products of cellular processes. Driving these cellular processes are
layers of regulation that consists of protein and mRNA that are derived from the organism’s
DNA. Metabolomics broadly studies four classes of metabolites, namely carbohydrates, lipids,
amino acids and nucleotides. Knowledge gleaned from metabolomics would complement
transcriptomics and proteomics studies.
Living systems acquire and utilize free energy through metabolism to carry out
various functions such as generation of energy and biosynthesis of larger complex
biomolecules (Voet & Voet, 2004a). The reactants, intermediates and products in
metabolism are referred to as metabolites and are produced by enzymes that can be
regulated by upstream cellular processes such as gene expression. Since metabolites
are the end-products of cellular activity and regulation, they represent the downstream
phenotypic response of a biological system and quantitative information about
metabolite levels are likely to reveal unique insights about disease and toxicological
responses (Fiehn, 2002; Nicholson, Lindon, & Holmes, 1999a). Metabolomics is a
relatively new high-throughput profiling technology and is fitting for revealing such
4insights as it measures metabolites in biological samples in a global and unbiased
manner. The detectable metabolites include carbohydrates, amino acids, nucleobases
and lipids.
Fig. 1.2 Number of metabolomics-related publications by year. Metabolomics-based
studies have been on the rise since early 2000s, reaching around 1400 publications in 2013.
(Last accessed 31th March 2014 from PubMed with search term “metabolomics”)
In contrast to traditional reductionist and hypothesis-driven research, metabolomics
adopts an exploratory and discovery-driven approach. Such an approach aims to
reveal collective responses generated by the biological system and further identify
metabolites that have significant biological value. When applied to a hypothesis-
driven research, metabolomics can also uncover differential responses and key
metabolites affected using comparative methods (Patti, Yanes, & Siuzdak, 2012). As
such, metabolomics can provide significant value in biomedical and environmental
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5has been steadily recognised by research laboratories as reflected by the recent trends
of publications utilizing metabolomics (Fig. 1.2).
1.1.2 The role of metabolism and its implication in biological responses
1.1.2.1 Metabolism provides free energy to carry out biological functions
Metabolism is the overall process through which living systems acquire and utilize the
free energy they need to carry out their various functions such as mechanical work,
active transport of molecules against concentration gradients, and the biosynthesis of
complex molecules (Voet & Voet, 2004b). Free energy or Gibbs free energy (G) is a
thermodynamics quantity describing the energetics of a system (Fig. 1.3) and the
change in free energy (ΔG) indicates the spontaneity of a chemical reaction. If the ΔG
is negative (ΔG <0), the chemical reaction is exergonic and can be utilized to do work
(Fig. 1.3A), whereas if it is positive (ΔG >0), the reaction is endergonic and would
require input of free energy to drive it (Fig. 1.3B).
Living systems are hence maintained by a vast metabolic network that couples the
exergonic reactions of nutrient oxidation (e.g. glycolysis) that generate free energy to
the endergonic reactions (anabolism) that synthesize biomolecules from simpler
components (e.g. building proteins from simple amino acids). These chemical
reactions are catalyzed by enzymes and allow organisms to grow and reproduce,
maintain their structures, and respond to their environments.
6Fig. 1.3 The concept of free energy in metabolism. Free energy is the amount of energy
available to do work in cellular environments and drives biological functions. A exergonic
reaction causes a decrease in free energy would release energy (A) in the form of heat or
usable energy that can be coupled to endergonic reactions that increases free energy within
metabolites such as glucose (B).
Source: http://facstaff.cbu.edu/~seisen/EnergyAndMetabolism.htm
An example of how free energy is utilized can be found in the adenosine triphosphate
(ATP) molecule. ATP is a molecule commonly referred to as the “energy currency of
the cell” that stores energy (Fillingame, 1999) and much of its energy is stored in its
phosphoanhydride bonds (Knowles, 1980). Chemical energy is released upon the
exergonic hydrolysis of these bonds and it can used to drive biological activities. The
regeneration of the bonds are driven by events such as glycolysis where the exergonic
reactions provide free energy to drive the endergonic process of reforming the
phosphoanhydride bonds.
1.1.2.2 Specific metabolic pathways produce specific metabolites
Though a complex network of processes, metabolism consists of simpler metabolic
pathways, which are essentially series of consecutive enzymatic reactions that
produce specific metabolites (Fig. 1.4). The implications of these pathways are vast
7for a biological system as specific metabolites are produced for specific roles. For
example, carbohydrates are essential for energy metabolism and for the glycosylation
of proteins to mediate receptor-recognition and immunity. Amino acids are the
building blocks for all proteins and lipids are an integral part of cell membranes and
forms part of signal transduction pathways.  As precursors to nucleotides, nucleobases
eventually form mRNA and DNA through RNA and DNA polymerase action
respectively.
8Fig. 1.4 Overview of metabolic pathways. Multiple distinct metabolic pathways work
together to provide metabolites to support the functioning of biological systems. Amongst
them are key pathways such as carbohydrate, amino acid and lipid metabolic pathways that
are often implicated in metabolomics studies.
Source: KEGG (Kyoto Encyclopedia of Genes and Genomes)
91.1.2.3 Differential metabolite levels are driven by enzyme regulation
Metabolic pathways are a series of connected enzymatic reactions that produce a
specific class of metabolite. The production of different classes of metabolites is
regulated by controlling enzyme activities in the relevant pathway. The rate-limiting
step or the first committed step of each pathway are important junctures to control the
overall production, hence differential metabolite levels can be achieved by regulating
the enzymes involved at these junctures (Rognstad, 1979).
Enzymes can be regulated via four mechanisms which are namely allosteric control,
covalent modification, substrate cycles and genetic control. Allosteric regulation
refers to the regulation of enzymes using substrates, products or coenzymes that are
not necessarily part of the enzyme (Cornish-Bowden, 2014; Monod, Changeux, &
Jacob, 1963).  Phosphofructokinase (PFK) is one such enzyme that is regulated by
adenosine monophosphate (AMP) (Wegener & Krause, 2002). Enzymes may also be
regulated by enzymatic phosphorylation of specific side chains (e.g. serine, threonine,
tyrosine) and such covalent modification can greatly alter enzyme activity (Klöck &
Khosla, 2012). Substrate cycling refers to the event where two metabolic pathways
that catalyze opposite reactions are occurring simultaneously. This results in the no
net substrate-to-production conversion and only energy is depleted and heat is
produced (Boiteux & Hess, 1981; Samoilov, Plyasunov, & Arkin, 2005; Schwender,
Ohlrogge, & Shachar-Hill, 2004). These three regulatory means are referred to as
“short-term” control mechanisms as they can respond rapidly to stimuli (within
seconds or minutes).
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Genetic control, on the other hand, represents a “long-term” mechanism. Genetic
control of enzymes functions through the control of enzyme concentrations by
altering protein synthesis that creates enzymes (Patil & Nielsen, 2005). Hence this
mechanism can only respond within hours or days and is hence referred to as “long-
term”. In response to disease and toxicological exposure, genetic control would likely
be a key mechanism in regulating metabolic pathways.
1.1.2.4 Discovering perturbed pathways and potential biomarkers
As mentioned earlier, specific metabolic pathways would produce specific
metabolites as intermediates or products. Hence through the identification of
differential metabolites, the metabolites can be mapped onto metabolic pathways to
infer the potentially regulated pathways. The pathway information gleaned would
provide a broad overview of perturbations occurring within the entire metabolism
network and allow researchers to relate metabolic pathway alterations to the disease
or stressor. Further exploration of the metabolic pathways would reveal the associated
enzymes and possible regulatory mechanisms (e.g. decreased gene expression of a
certain enzyme) to provide potential biological targets for future investigation if
desired.
More importantly, the differential metabolites themselves can be evaluated for their
usefulness as potential biomarkers. Biomarker discovery can be performed on the
acquired measurements and provide useful indicators for assessing the biological state
of the system.
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1.2 The discovery process in metabolomics
The discovery process in metabolomics first begins with a biological question and that
determines the appropriate sample type required and downstream experimental design.
Experiments in biomedical and environmental research often need involve in vitro, in
vivo or human population studies to test out their hypotheses, where each chosen
model has its own strengths, complexity and limitations. As each sample type differs
in complexity and variability, the experimental design should attempt to overcome
these factors and strive to make comparisons between groups as reliable as possible.
Therefore the success of a metabolomics experiment relies heavily on a well-
considered experimental design.
1.2.1 Experimental design
The quality of data in metabolomics is very crucial to ensure successful detection of
biological variation and to ensure that the data quality is good, a proper design of the
experiment is of high importance (Gibon & Rolin, 2012). A good experimental design
not only controls for variability based on the sample type, but further ensures that the
metabolic profiles in the collected samples are accurately captured, stably stored and
reliably processed prior to MS analysis. (Fig. 1.5).
1.2.1.1 Sample type and variability reduction
The design of sample collection places emphasis on removing systemic bias that
could skew downstream analysis, hence the first step involves identifying factors that
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can introduce bias/error in the experiment workflow. One common factor that could
distort results is the batch effect (Leek et al., 2010). Batch effect arises from the use of
different batches of living organisms or from different operating conditions of
instrument/reagent. Often, batch effect is detected when the data are found to not
correlate with variables of interest, but instead with different batches of organisms,
reagents and instrument operating conditions. Hence batch effect introduces
systematic variation that are of a confounding nature and could mask the true
biological effects (Scherer, 2009).
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Fig. 1.5 Key considerations in designing a
metabolomics experiment. In metabolomics,
experiments are carefully designed from the initial
sampling process to the final injection sequence.
During the collection of each sample type, the
process itself may introduce undesired variability
in the form of batch effect or confounding factors.
The sample integrity and metabolic profile is
preserved by quenching metabolism and
refrigerating samples as freeze-dried forms where
possible. Suitable solvents and extraction
procedure can provide a broad range of
detectable metabolites and randomized sample
injection can overcome instrument drift to improve
data reliability. (Original thesis figure by SM
Huang)
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In cell culture, batch effect could arise from using different vials of frozen cells to
propagate instead of using a single vial of frozen cells. In animal models such as the
zebrafish embryos, batch effect can occur when using eggs fertilized by different
mating pairs. Such effect has also been observed in microarray analysis of separate
mice litters (Carter et al., 2003). To mitigate this batch effect, the use of a single egg
source or the pooling of various egg sources can help distribute eggs evenly.
In human population samples, the high complexity and variability of the samples
require experimental designs that focus on recruiting a near-homogenous pool of
subjects to eliminate confounders. They are typically qualified for inclusion by
matching factors such as age, gender, health status and lifestyle habits before their
samples are used in a metabolomics experiment. On top of eliminating confounders,
careful sample preparation and sample injection is needed to avoid introducing batch
effect during data acquisition.
1.2.1.2 Sample collection
In vitro and in vivo samples contain cells that are capable of metabolism and in order
to ensure a more accurate measurement of metabolites, the metabolism within these
live samples needs to be quenched. Metabolism quenching can be achieved by the use
of rapid cooling methods such as snap freezing in liquid nitrogen or by washing the
samples with cold buffer solutions. After quenching is performed, proper storage of
samples is necessary to minimize sample degradation. For cell and animal samples,
this can be best achieved by freeze-drying (lyophilizing) samples into dry powder and
further storing them under -80°C conditions.
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Urine samples from humans typically do not require quenching as they are essential a
biofluid and are not as prone to metabolic changes as cells or animal samples. Urine is
typically collected as midstream urine in the morning when practicable. This is
followed centrifugation of urine at 16 relative centrifugal force (rcf) (4°C, 10min) to
sediment particulate matter prior to storage at -80°C.
1.2.1.3 Sample preparation
Before any acquisition of data can commence, the metabolites from samples need to
be extracted with a solvent such as methanol, acetonitrile, chloroform or a mixture of
these with water. In our studies, we adopt the use of pure methanol which can extract
a wide range of metabolites. Methanol is also further spiked with a known and fixed
amount of internal standard, 9-Fluorenylmethoxycarbonyl-glycine (FMOC-glycine) to
correct for technical variations.
For cells and animal samples, we apply the use of ultrasonication to enhance the
extraction process. The sonication process also causes samples to homogenize due to
the intense agitation of particles. Typically methanol is added to the freeze-dried
sample and sonicated in an ultrasonication ice water bath at 4°C. The ice water bath
mitigates the heat generated from intense sonication and ensures minimal sample
degradation. In the event that samples are large solids that are relatively harder to
homogenize using ultrasonication, glass/steel beads are used to homogenize the
samples prior to extraction.
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Urine samples require a different sample preparation process due to the high amount
of urea present that could suppress ionization of other ions. Typically urine samples
are pre-treated with urease to degrade urea before extraction with methanol.
1.2.1.4 Sample injection order
Analytical instruments such as the mass spectrometry are prone to instrument drift (i.e.
the detection can be variable over time, see Table 1.1). This presents yet another
challenge in acquiring reliable results in metabolomics experiments with large sample
size. To mitigate this instrument drift, samples can be randomized to ensure that the
instrument drift is not correlated with the sample sequence and that any detected
variation can be confidently attributed to biological effects (Burton et al., 2008).
1.3.1 Analytical Instruments
The metabolomics discovery process is a departure from traditional methods and it is
markedly different due to its philosophy of collectively analyzing multiple features
simultaneously. A feature is defined as a spectral signal that stems from the detection
of a molecular species using analytical instruments. In this thesis, the mass
spectrometer (MS) is the main instrument for detecting masses eluted from liquid
chromatography (LC) and gas chromatography (GC). The mass spectrometer and
chromatography are commonly combined together to exploit advantages of chemical
separation and sensitive mass detection. Such systems are commonly referred to as
hyphenated techniques.
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1.3.1.1 LC-MS and GC-MS as key analytical instruments
LC-MS and GC-MS are commonly used hyphenated techniques in metabolomics.
Each technique detects a different range of metabolites and hence they are used in
metabolomics to provide broader detection coverage. LC-MS is ideal for analyzing
metabolites that are less polar or non-polar, e.g. aromatic amino acids, nucleosides
and lipids respectively. GC-MS on the other hand is specialized for analyzing polar
metabolites that have been derivatized using derivatizing agents. Nuclear magnetic
resonance (NMR) is another popular instrument for metabolomic analysis, however it
suffers from lower sensitivity. A comparison of MS and NMR’s capabilities for
metabolomics are presented in Table 1.1. In this thesis, we employed LC-MS and
GC-MS to achieve broader detection capabilities and higher sensitivity to better
capture metabolic responses of biological systems (Fig. 1.6).





Sensitivity for low abundance metabolites High Low
Ability to process large sample size Strong Poor
Amount of sample required Relatively lesser Relatively more
Metabolite Identification Relatively poor Relatively better
Instrument drift/batch effect Prone to drift Relatively stable
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Fig. 1.6 Increasing metabolite detection coverage of metabolites. The chemical diversity
in biological samples are broad with wide-ranging polarities. Using both GC-MS and LC-MS,
the coverage of metabolites can be potentially widened and this can deliver a more complete
information for biological insights.
1.3.1.2 Derivatization of metabolites for GC-MS
GC-MS is an analytical instrument designed for the separation and detection of
volatile compounds. With the use of derivatizing agents (methoxyamine and N-
Methyl-N-(trimethylsilyl) trifluoroacetamide (MSTFA)), compounds that are less
volatile can be chemically modified into volatile derivatives and be analysed by GC-
MS. The transformation of metabolites into volatile derivatives is achieved by
converting -NH and -OH groups to the non-polar trimethylsilyl (TMS) group. This
derivatization process (Fig. 1.7) can hence allow polar and non-volatile metabolites to
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be analysed using GC-MS and complement the range of metabolites analysable by
LC-MS (Fig. 1.6).
Fig. 1.7 Derivatization of fructose for GC-MS. Using methoxyamine and MSTFA, the
carbonyl group and hydroxyl groups of fructose are respectively replaced by an oxime
derivative and a trimethylsilyl group. These groups reduce the polarity of fructose and also
increase it volatility, making the derivatized fructose suitable for chromatographic separation
in GC-MS.
1.3.1.3 Ionization modes in LC-MS and GC-MS and its implications for data
analysis
In mass spectrometry (MS), the metabolites are channelled towards the mass detector
by manipulating them with electric fields. This necessitates for the presence of charge
on the metabolite as the electric field would not have any effect on uncharged
molecules. Therefore in MS, only charged molecules or ions are detectable and the
process of imparting charge to molecules is referred to as ionization.
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Ionization in metabolomics can be achieved by electrospray ionization (ESI) in LC-
MS (Yamashita & Fenn, 1984) or electron ionization (EI) in GC-MS. ESI involves
the pumping the LC eluent through a narrow capillary. High voltage is applied to the
capillary as the eluent is ejected from the capillary, the surface of the eluent droplets
become charged and soon disperse into a Taylor cone of finely dispersed charged
droplets (Fig. 1.8 top). The droplets are evaporated by dry nitrogen gas during the
dispersal process and eventually become charged adduct ions (i.e. molecules with an
charged adduct e.g. [M+H]+). ESI is also known as a ‘soft’ ionization method as it
does not fragment the precursor ion M.
In EI, the GC eluent is bombarded with a high energy electron beam (70eV) and
precursor ions are then charged either through the formation of a positively charged
free radical or the instability of the free radical ion may cause the ion to fragment into
smaller charged fragments. This ionization mode is known as ‘hard’ as the precursor
ion is fragmented by the electron beam (Fig. 1.8 bottom).
The different nature of these ionization methods gives rise to two forms of mass
spectra – one with few fragments (LC-MS) and one with large number of fragments
(GC-MS). Hence in GC-MS, though the number of detected features may be large, it
may not correspond to a large of detected metabolites as the diversity arises from
fragments instead of bona fide precursor ions.
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Fig. 1.8 Chromatography and ionization methods for mass spectrometry-based
metabolomics. Metabolites are extracted from samples and injected into the chromatography
system for separation and subsequent mass detection. Depending on the chromatographic
step, the extract may require a derivatization step (GC-MS). During the separation process,
conditions such as temperature or solvent composition would be varied to allow a controlled
elution of metabolites based on their chemical properties. As mass spectrometers can only
detect ions, the eluted metabolites are ionized using ESI or EI. In ESI, the metabolites are
dispersed as small droplets by the high voltage capillary and become unfragmented adduct
ions, whereas in EI, the electron beam causes metabolites to lose electrons and become
charged radicals or fragment into smaller charged molecules. (Original thesis figure by SM
Huang)
1.3.2 Data analysis in metabolomics
In metabolomics studies, large volumes of data are generated from the analytical
instruments and it is a non-trivial task to pre-process and analyze them. Raw spectral
data are encoded in vendor-specific formats that may only be accessed using vendor-
provided software. Fortunately, open data formats such as mzXML (S. M. Lin, Zhu,
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Winter, Sasinowski, & Kibbe, 2005; Pedrioli et al., 2004) and mzData (Orchard et al.,
2007) have allowed portability of raw data across computers. This however is but the
first step in the long complex process of metabolomics analysis. The subsequent
subsections will elaborate the complex process of analyzing metabolomics data from
raw data to interpretable metabolic pathways (Fig. 1.9). As part of data-sharing,
online data storage & availability to other researchers have also been advocated
through repositories such as MetaboLights (Haug et al., 2013) and Metabolomics
Workbench (http://www.metabolomicsworkbench.org).
1.3.2.1 Pre-processing
Peaks or features need to be detected from raw data as this is essential for generating a
peak table that forms the basis of further analysis (Tomita, Kawakami, Soga, Robert,
& Sugimoto, 2012). Peak detection can be performed manually or through computer
algorithms provided by peak detection software. In manual detection, the experienced
chromatographer scrutinizes the raw chromatogram and highlights regions of
sufficient signal-to-noise ratio as peaks/features. Although this approach is labor-
intensive and prone to operator-bias, experienced chromatographers may detect peaks
left out by computer algorithms.
In contrast to the manual approach, computer algorithms have been designed to detect
peaks based on rules and mathematical modelling. Prominent examples of such
algorithms are present in software such as xcms (Tautenhahn, Böttcher, & Neumann,
2008; Tautenhahn, Patti, Rinehart, & Siuzdak, 2012) and mzMine (Pluskal, Castillo,
Villar-Briones, & Oresic, 2010). The obvious benefits of using computer algorithms
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are the faster detection speed and reduced operator-bias. However, users may have to
overcome the software learning curve and optimize the settings before arriving at a set
of well-detected peaks. Hence though computer algorithms are expedient, they may
still be imperfect.
Fig. 1.9 The metabolomics discovery and analytical process can be generalized into six
steps. Experimental design is important in managing the inherent variability of specific
sample types (e.g. human samples are more variable than cell line samples). Upon acquiring
spectral data from instruments, pre-processing is necessary to generate a list of
peaks/features for downstream multivariate and univariate analysis. Metabolite identification
is performed based on shortlisted candidates deemed to be significantly altered due to
disease or toxicological exposure and these metabolites would be analysed in the context of
metabolic pathways to reveal its biological significance.
(Original thesis figure by SM Huang with images of No. 3 & 6 sourced from
http://ordination.okstate.edu/PCA.htm & KEGG respectively)
1.3.2.2 Normalization of Peaks
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The normalization of peaks is essential to correct for technical variation that may
occurred during the course of instrument analysis. Broadly, there are three main
approaches for normalization in metabolomics and they include using internal
standards, applying statistical normalization and normalizing peaks with the total ion
chromatogram (Bolstad, Irizarry, Astrand, & Speed, 2003).
Internal standards (IS) are fixed amounts of chemical substances intentionally spiked
into the sample prior to extraction and analysis. They should ideally be exogenous
substances not found in biological samples and be well-detected by the analytical
instrument.  As the IS are fixed in amount, any fluctuations in the instruments can be
adjusted based on the IS signal to provide a good normalization.
Statistical normalization is another common form of adjusting for technical
variation/fluctuation. A broad range of methods have been developed and amongst
them, quantile normalization is well-favored by publications for its simplicity and
robustness (Bolstad et al., 2003). Essentially, the peak values of multiple samples are
made identical in statistical distribution through a mathematical process and this
allows for easier comparison between samples.
Total ion chromatogram (TIC) normalization attempts to correct for technical
variation/fluctuation by dividing peak intensities with the overall TIC value. Recently,
Sysi-Aho et al. have demonstrated that this method may give rise to erroneous
conclusions. Experiments have shown that given the overproduction of certain
metabolites, the TIC increases and hence reduces the normalized value of other peaks,
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giving rise to the impression of a downward trend (Sysi-Aho, Katajamaa, Yetukuri, &
Oresic, 2007) (Fig. 1.10).
In this thesis, we apply the use of an internal standard, 9-Fluorenylmethoxycarbonyl-
glycine (FMOC-glycine) as a means to normalize our peak data. The internal standard
normalization was favoured as systematic variation can be empirically adjusted for.
As an internal standard, FMOC-glycine gives a reproducible and characteristic peak
in both GC-MS and LC-MS, and it elutes in the middle of a typical chromatography
run.
Fig. 1.10 The potential pitfall of total ion chromatogram (TIC) normalization. Two mouse
liver lipid profiles are drawn to scale, where one is from obese ob/ob mouse and the other
from lean wild type mouse. While the phospholipid profiles are similar in total amount, there is
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a large increase in triacylglycerols in obese mouse. Normalization based on TIC would
wrongfully decrease the levels of phospholipids in obese mouse relative to the wild type to
balance the increased amount of triacylglycerols. (Adapted from Sysi-Aho et al., 2007).
1.3.2.3 Multivariate analysis
Metabolomic data are generally high-dimensional (i.e. consists of large number of
peaks) and this is not well-suited for traditional methods of single variable
comparisons. In order to analyze and meaningfully compare such data, multivariate
analysis (MVA) has been applied to metabolomic data to handle the high-
dimensionality and simplify interpretation.
MVA refers to a family of mathematical tools aimed at reducing the high-dimensional
data into lower, interpretable forms. In metabolomics, the use of principal component
analysis (PCA), partial least squares-discriminant analysis (PLS-DA) and orthogonal
partial least squares-discriminant analysis (OPLS-DA) are prominent in publications
(Trygg, Holmes, & Lundstedt, 2007). PCA represents an unsupervised method of
analysis, where sample observations are not labeled with known properties (e.g.
control or case). Here the PCA method reduces the high dimensional data into a few
variables (principal components) that can explain most of the original data (Fig. 1.11).
This is a useful means of comparing differences between observations in an unbiased
manner. In supervised methods (PLS-DA, OPLS-DA), the labelling information is
used to mathematically model the data for the classification of observations. It is a
useful process for improved interpretation of data (Fig. 1.12) as well as for
discovering influential peaks that best explain the differences between labelled groups.
In PLS-DA (Wold & Sjostrom, 2001) and OPLS-DA (Bylesj et al., 2006), the
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variable importance in the projection (VIP) value is a measure of such influence,
where any VIP > 1.0 is considered significant.
Fig. 1.11 Principal component analysis (PCA) reduces high dimensional data into a
lower number of explanatory variables. Here a three-dimensional dataset is converted into
a simpler two-dimensional component space by mathematically finding variables (principal
components) that describe the highest variance in the data. PCA is particularly useful when
high-dimensional metabolomics dataset consists of hundreds to thousands of peak features.
Source: http://www.nlpca.org/pca_principal_component_analysis.html
Fig. 1.12 A comparison between PCA, PLS-DA and OPLS-DA. PCA is an unsupervised
method that does not utilize knowledge of sample classes, hence it simplifies and projects
data to lower dimensions using principal components in an unbiased manner. PLS-DA and
OPLS-DA are mathematical extensions of PCA that requires knowledge of sample class.
Their algorithms would attempt to model data based on such knowledge and this results in
better clustering of observations and a goodness of prediction score (Q2). OPLS-DA
improves visual interpretability by separating predictive information into the first component





The next step after multivariate analysis would be to apply univariate tests on
influential peaks to test for statistical significance. Two types of univariate tests are
routinely applied to metabolomics data – namely parametric and non-parametric tests.
Parametric tests such as t-test and ANOVA are suitable for peaks that are continuous
variables and that have normally distributed values. Conversely if the peaks are not
normally distributed, the use of non-parametric tests are warranted (Mann-Whitney U
and Kruskal-Wallis) or the peaks can be logarithmically transformed to fulfill the
normality assumption of parametric tests. A detailed review of pre-processing &
analysis standards can be found in the Metabolomics Standards Initiative (MSI)
(Goodacre et al., 2007).





Two groups t-test Mann-Whitney U
More than two groups ANOVA Kruskal-Wallis
1.3.2.5 Peak shortlisting and identification
With variable importance and statistical significance calculated in previous steps,
peaks are shortlisted based on VIP (>1.0) and p-values (<0.05). Each peak consists of
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a mass-to-charge ratio (m/z) and retention time index (RT), which provides the basic
chemical information required for metabolite identification.
Further accurate identification typically involves tandem MS, a process that ‘breaks’
selected ions into a characteristic spread of smaller fragmented ions. The spectra of
fragmented ions are compared against databases to determine the identity of the
metabolites. Well-known databases such as the Human Metabolome Database
(HMDB) (Wishart et al., 2009), METLIN (Tautenhahn, Cho, et al., 2012), MassBank
(Horai et al., 2010), NIST (Babushok et al., 2007) and Lipid Maps (Fahy, Sud, Cotter,
& Subramaniam, 2007) are routinely used by metabolomics investigators to aid in
metabolite and pathway identification (Fig. 1.13). The Metabolomics Standards
Initiative (MSI) provides guidance on reporting standards (Sumner et al., 2007).
Fig. 1.13 Databases are integral to metabolomics research and they are essential for
metabolite identification and discovering biological pathways. The human metabolome
project (HMP) provides the human metabolome database (HMDB) for matching and verifying
MS and NMR data. METLIN and MassBANK are also databases for verifying potential leads
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but they are reserved for MS data. NIST is used to identify metabolites detected in GC-MS.
The small molecule pathway database (SMPDB), Kyoto encyclopaedia of genes and
genomes (KEGG) and Lipid Maps are resources for understanding biological pathways found
to be significantly altered in metabolomics studies.
1.3.2.6 Biological Inference
Having measured and identified metabolites, the next step would be to generate
insights on metabolic pathways that were collectively responding to disease or
environmental stressors. Metabolites are derived from specific pathways in the
complex metabolism network, hence by mapping metabolites onto their respective
pathways, a broader systems perspective on metabolic change can be observed. Key
resources for mapping metabolites are the Kyoto Encyclopaedia of Genes and
Genomes (KEGG) (Kanehisa, Goto, Sato, Furumichi, & Tanabe, 2012) and the Small
Molecule Pathway Database (SMPDB) (Frolkis et al., 2010) (Fig. 1.13). After
metabolomics have provided some hypotheses on biological pathways affected, these
would require experiments to support it.
1.4 Objective of thesis: the application of metabolomics to biomedical and
environmental studies
In the thesis, metabolomics was applied to biomedical and environmental research,
where we attempted to elucidate exposure effects to toxicants, disease etiologies and
discover useful biomarkers. The specimens investigated spans from in vitro, in vivo to
human samples. This broad scope of samples necessitated different strategies to
overcome inherent sample complexity and variability. To assess the applicability of
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this relatively new technology to these different sample types, a detailed
understanding of factors underlying the differential complexity and variability was
carried out (Fig. 1.14). Experimental designs should factor in the complexity and
variability of different samples and this forms the first and most important step of
metabolomics.
Fig. 1.14 Biomedical and environmental samples used in metabolomics may have
different complexity and variability. Of the lowest complexity and variability are the in vitro
samples, which are of a single cell type and genetic makeup. In vivo samples exhibit higher
complexity due to its multiple cell type / organ system and higher variability owing to its
variable genetic makeup. Human samples represent the most complex and variable sample
type as they have a multiple organ system coupled with variable diet, lifestyle and genetic
factors.
Cell lines are the key biological systems used in in vitro studies and represent the
sample type of lowest complexity and variability in this thesis.  Each cell line is of a
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specific cell type and consists of a population of cells that were grown from a single
cell. Compared to a complex organism, cell lines are simplified systems that not only
have a singular cell type but also genetic uniformity among all cells. Beyond the
genetic uniformity, cells are also cultured in specific growth media and external
conditions that are well-controlled and constant.  The application of metabolomics in
cell lines is explored in Chapter 2, where human fetal lung fibroblasts (MRC-5) were
cultured and exposed to nanosilica to elucidate toxicological responses and
biomarkers (Huang et al., 2012). The variability of samples was controlled through
the use of a single batch of cells that were cultured in a defined and controlled
environment.
Animal models are useful tools for in vivo studies that aim to assess the collective and
representative response of an organism. The results obtained from animal models can
be better extrapolated to humans than simplified cell lines. However the challenge in
working with animal models are their higher complexity and variability. As higher
life forms, animal models consists of multiple tissue types and each animal is also
different in genetic composition. Despite being able to control for growth and diet
conditions, samples from animal models are nonetheless more complex and variable.
Chapter 3 examines and discusses the feasibility of applying metabolomics to
zebrafish embryos, an increasingly popular animal model for biomedical and
environment research. Upon having established and optimized methods for the
zebrafish-metabolomics platform (Huang, Xu, Lam, Gong, & Ong, 2013), this
platform was deployed to study the toxicological effects of water pollutants of public
health concerns, specifically N-nitrosodimethylamine (NDMA). The variability of
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zebrafish embryo-based experiments lies in the occurrence of batch effect, where
different batches/clutches of eggs may give rise to detectable biological variation.
Hence for NDMA-treated embryos, they belonged to a singular batch/clutch of
fertilized eggs to reduce this occurrence.
As most biomedical and environmental research are geared towards enhancing human
health and well-being, the collection of human samples would be most suitable for
understanding disease mechanisms and toxicological responses. However human
subjects are not only complex and diverse in genetic composition, but also different in
diet, lifestyle and environmental conditions. These factors of diet and lifestyle are
difficult to control for and hence human samples represent the sample type of highest
complexity and variability. In Chapter 4, we studied a unique group of diabetic
patients from the Singapore Diabetes Cohort Study (SDCS). Despite suffering from
chronic kidney disease (CKD), these patients exhibit no abnormal level of protein in
their urine. Through metabolomics analysis of their urine samples, it was aimed to
discover biomarkers that could discriminate this specific group of patients and
improve the current state of diagnosis. In a population study that consists of highly
variable individuals, the characteristics such as age, gender and BMI were accounted
for to improve the robustness of this study (Ng et al., 2012a).
In Chapter 5, the challenges of metabolomics analysis would be discussed based on
issues such as the poor streamlining of software tools and database queries. In order to
resolve these challenges, a software called MetaboNexus was developed by the author.
This software is capable of streamlining the entire metabolomics analytical process to
provide both an expedient and optimizable user experience (Huang, Toh, Benke, Tan,
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& Ong, 2014). The concluding Chapter 6 would discuss about the insights and
limitations brought about by metabolomics, conclude about our findings and briefly
envision the outlook of metabolomics.
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Chapter Two
Toxicological evaluation of silica
nanoparticles using an in vitro model
This work has been published in Advanced Healthcare Materials (2012)
Huang SM, Zuo X, Li JJ, Li SF, Bay BH, Ong CN. Metabolomics studies show dose-
dependent toxicity induced by SiO(2) nanoparticles in MRC-5 human fetal lung
fibroblasts. Advanced Healthcare Materials. 2012 Nov;1(6):779-84
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Project Abstract
Rationale: Nanosilica are extremely fine particles of silica (SiO2) that are <100nm in
at least one dimension. Increasingly, nanosilica can be found in consumer products
(e.g. cosmetics and sunscreens), as well as drug therapeutics. As these particles are
nanosized, they exhibit different physicochemical properties from their normal bulkier
forms. This gives rise to concerns that exposure to nanosilica may cause unintended
adverse effects.
Hypothesis: The effect of nanosilica on biological systems is poorly understood and
we hypothesize that while silica is relatively non-toxic, the nanosized silica may exert
toxicological effects due to its unique physicochemical characteristics.
Objective and Methods: We aim to reveal biological effects of nanosilica (~45nm)
using an in vitro model and evaluate its effects using morphological, biochemical and
metabolomics approaches. The use of in vitro testing allows for a high degree of
control over variability and also reduces complexity of samples. Morphological
observations provide qualitative assessment of exposure effects, while biochemical
assays can measure specific induced molecular changes. Untargeted metabolomics
can strengthen the first two approaches by globally identifying perturbed metabolites
related to exposure.
Measurements and Main Results: Confocal microscopy revealed dose-dependent
uptake of nanosilica, although morphological observations and cell viability assays
did not show significant changes in cell growth nor death of MRC-5 cells. Beyond
morphology, we applied oxidative stress assay and metabolomics where dose-
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dependent effects were revealed. Firstly, amino acids were significantly decreased
with a concomitant rise of urea, suggesting active deamination. Increased oxidative
stress and phospholipid levels were also observed. Ultrastructural investigations
revealed that the number and size of vacuoles increased in response to higher doses of
nanosilica.
Conclusions: Although there were no effects on cell viability and morphology,
nanosilica exerted dose-dependent effects on the MRC-5 cell line, mainly through
oxidative stress and perturbations of amino acid and phospholipid metabolism. The
increased vacuolization within the cells may be related to the metabolic perturbations.
In this study, we demonstrated the complementary role of untargeted metabolomics to
specific methods (e.g. cell viability, oxidative stress) in an in vitro model. The
pathway changes observed may be of interest to nanosilica researchers and provide





Nanosilica (SiO2NP) is a commonly used nanomaterial in industrial and research
settings (Blute, Pugh, van de Pas, & Callaghan, 2009; Zhong, 2009) and with its
increased presence in consumer goods, the toxicity of SiO2NP needs to be elucidated.
It is well known that exposure to silica dust leads to silicosis, a common occupational
disease in China (X.-R. Wang & Christiani, 2003). SiO2NP being nanosized (<100nm)
is much smaller than silica dust and nanosized particles may have altered
physicochemical characteristics that could result in a different toxicity from the
bulkier silica particles (Napierska, Thomassen, Lison, Martens, & Hoet, 2010).
Recent studies have revealed that  SiO2NP exposure exerts effects (Napierska et al.,
2010) such as cytotoxicity (Chang, Chang, Hwang, & Kong, 2007), global genomic
hypomethylation (Gong et al., 2010) and alteration of protein expression in cells
(Yang et al., 2010). Numerous efforts have also been channeled towards the
pathological, genomic and proteomic effects of SiO2NPs exposure. Alongside these
recent developments, there is also an incipient interest in applying metabolomics to
nanotoxicity (Lu et al., 2011) but knowledge of how basic metabolic perturbation
occurs due to such exposure still remains to be expanded. Here, we seek to address
this knowledge gap by assessing the biological effects of SiO2NP using cell culture
and metabolomics.
Metabolomics is defined as “the quantitative measurement of the dynamic
multiparametric metabolic response of living systems to pathophysiological stimuli or
genetic modification" (Nicholson, Lindon, & Holmes, 1999b) and its use in
nanotoxicity is a relatively new approach. Firstly, MRC-5 fetal lung fibroblasts were
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cultured and treated with increasing doses of SiO2NP (0, 2.5, 10, 40 and 80 µg/mL)
for 24h. The cells were then observed for overt cell morphological changes and
assayed for cell viability and oxidative stress. Subsequently, the cells were harvested
and analysed using mass spectrometry and statistical analysis to elucidate their
metabolomics profiles. In mass spectrometry, both liquid chromatography (LC) and
gas chromatography (GC) were used to separate the cellular extract in chemically
distinct and complementary ways prior to mass detection.
LC is suitable for the separation of relatively non-polar compounds such as aromatic
compounds and lipids, whereas GC is well-suited for separating polar compounds that
have been chemically derivatized for metabolomics experiments. In combination, they
effectively broaden the qualitative detection range of mass spectrometers for a
comprehensive metabolomics study.
2.2 Materials and Methods
2.2.1 SiO2NP synthesis
SiO2NP were synthesized by reverse microemulsion method (Bagwe, Yang, Hilliard,
& Tan, 2004). Briefly, 1.77 mL of Triton X-100, 7.5 mL of cyclohexane and 1.6 mL
of n-hexanol were firstly mixed in a 25 mL round bottom flask with continuous
magnetic stirring followed by introducing 0.4 mL of H2O. Then 100 mL tetraethyl
orthosilicate (TEOS) was added and the materials were stirred for 30 min. To initiate
the hydrolysis and silica polymerization of TEOS, 60 μL 25% NH4OH was added.
The mixture was allowed to stir for 18 h followed by the addition of acetone to break
the microemulsion. The particles were recovered by centrifugation and then washed 3
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times with ethanol and ultrapure H2O respectively. The nanoparticles were
subsequently incubated with fetal bovine serum (FBS) at 4˚C for 12 h to mimic the
real event, since nonspecific protein absorption is known to occur when foreign
materials enter human body. Then the nanoparticles were washed in phosphate buffer
saline (PBS) to remove excess FBS. To prepare fluorescent SiO2NPs, a similar
procedure was carried out but aqueous fluorescent dye (Tris(2,2’-
bipyridyl)dichlororuthenium(II) hexahydrate) solution was added instead of H2O.
2.2.2 Cell culture
MRC-5 fetal lung fibroblast (ATCC No. CC-171) were cultured in RPMI 1640 media
supplemented with 10 % fetal bovine serum and 100 units/mL penicillin, 100 μg/mL
streptomycin. Cell cultures were maintained in an atmosphere of 5% CO2 and 37˚C.
2.2.3 Treatment of MRC-5 with SiO2NP
MRC cells grown to 80% confluency in a 175 cm² flask were incubated with different
concentrations of SiO2NP (0 µg/mL, 2.5 µg/mL, 10 µg/mL, 40 µg/mL, and 80 µg/mL)
for 24 h.  The flask was put on ice and the medium was quickly removed followed by
swiftly washing the cells twice with ice-cold PBS. The cells were then harvested by
scraping and centrifugation. They were subsequently kept at -80oC, freeze-dried and
weighed. Metabolite extraction was carried out to isolate metabolites from the freeze-
dried cells.
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2.2.4 Metabolite extraction and chemical derivatization
Briefly, 350 µL MeOH with 10 mg/L FMOC-Glycine as internal standard was added
into the tubes containing freeze-dried cells, followed by 3 min of vortexing and 15
min of sonication at 4oC. The extraction was then centrifuged twice at 16.1 rcf at 4oC
for 10 min to sediment all possible particulates. 80 µL of the supernatant was used for
LC-MS analysis and 100 µL of the supernatant was aliquoted for chemical
derivatization for GC-MS analysis.
The derivatization was carried out in glass amber vials to shield light-sensitive
chemicals. Firstly, 100 µL of the supernatant was dried under N2 flow for 1 hour
followed by addition of 100 µL of 50 µg/mL methoxyamine in pyridine. The reactants
were mixed thoroughly under vortexing for 30 s and then kept at 37˚C for 2h.
Thereafter, the mixture was dried again under N2 flow and reacted with 100 µL of
MSTFA (N-methyl-N-(trimethylsilyl) trifluoroacetamide) at 37˚C for 16h for
silylation. Centrifugation of tubes were performed with 230 rpm at 4˚C for 1 min and
subsequently used for GC-MS analysis. Four biological replicates of each
administered dose were prepared and extracted for GC-MS and LC-MS.
2.2.5 GC-MS and LC-MS
The method used in the present was based on our earlier reports (Ng et al., 2012a;
Ong et al., 2010). In brief, 1.0 µL aliquot of the derivatized samples were injected
with the splitless mode with an Agilent 7683 Series autosampler (Agilent
Technologies) into an Agilent 6890 GC system equipped with an Agilent HP-5MS
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capillary column (30 m × 0.25 mm ID × 0.25 µm). The inlet temperature was set at
250oC. Helium was used as the carrier gas with a constant flow rate 1.00 mL/min
through the column. The initial GC oven temperature was set at 70oC, ramped at 10oC
/min to 250oC after 1 min of post-injection followed with ramping at 25oC /min to
300oC and then holding for 6 min. The total running time was 27 min. The transfer
line to the mass spectrometer was kept at 280oC. Detection was achieved using MS in
electron impact mode and full scan monitoring (m/z 50 to 550). The temperature of
the ion source was set at 230oC, and the quadrupole was set at 150oC. The solvent
delayed time was set as 3.9 min.
An Agilent 1200 HPLC (Waldbronn, Germany) equipped with a 6410 QQQ triple
quadrupole mass detector was used and managed by a MassHunter workstation.
Liquid chromatography was performed on a column of Agilent rapid resolution HT
Zorbax SB-C18 (2.1×50 mm, 1.8 µm; Agilent Technologies, Santa Clara, CA, USA).
The autosampler was kept at 4oC and the oven temperature was set at 50oC. The
gradient elution involved a mobile phase consisting of (A) 0.1% formic acid in water
and (B) 0.1% formic acid in MeOH. The initial condition was set at 5% B. The
following solvent gradient was applied: from 95% A and 5% B to 10% A and 90% B
within 10 min, held for 10 min and then to 100% B within 5 min and held for 10 min.
The flow rate was set at 0.2 mL/min and volumes of 5.0 µL of samples were injected.
The ESI-MS spectra were acquired in the positive ion mode. The ion spray voltage
was set at 4,000 V. The heated capillary temperature was maintained at 350oC. The
drying gas and nebulizer nitrogen gas flow rates were 10 L/min and 30 psi,
respectively. For full scan mode, analysis spectra were stored from m/z 100 to 1500.
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Collision energy was set in the range of 10 to 50 V depending on the stability of the
analytes when product ion scan modes were used. Neutral loss of 141 m/z was used to
help identify lysophosphotidylethanolamines (LPEs) and a combination of 59 m/z
neutral loss with characteristic 184 m/z peak were used to identify
lysophosphatidylcholines (LPCs).
2.2.6 Spectral data analysis
All the raw chromatograms data of GC-MS and LC-MS were pre-processed using
software of MZmine 2 and converted into two matrixes for GC-MS and LC-MS
respectively after m/z and retention time alignment. The intensity of each peak was
normalized to the sample dry-weight and internal standard (FMOC-glycine) to correct
for variations based on both the samples and technique. Metabolites which did not
exist in 50% of all samples were not taken into account (“50% rule” for missing
values, a modification from “80% rule”). The missing values were replaced with a
half value of the minimum in the data set.
The pre-processed data sets of GC-MS and LC-MS were imported into the SIMCA-
P11.0 software package (Version 11.0, Umetrics AB, Umea, Sweden) separately for
analysis and visualization by multivariate statistical methods. The data were then
mean-centered and unit variance scaled prior to OPLS-DA. Heat maps and Kruskal-
Wallis test were conducted using MultiExperiment View V 4.6.1 (www.tm4.org).
The criterion for statistical significance was set at p<0.05.
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2.2.7 MTS cell viability assay & cell area calculation
MRC-5 lung fibroblasts (ATCC No. CC-171) were seeded onto 96-well culture plates
at 4,000 cells/well. The cells were cultured for one day before treatment with 0
(control), 2.5 g/mL, 10 g/mL, 40 g/mL and 80 g/mL SiO2NP respectively. MTS
(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium) assay was carried out 24 h after SiO2NP treatment with the CellTiter
96® Aqueous Non-Radioactive Cell Proliferation Assay Kit (Promega, US). This
assay measures the formazan product of MTS metabolism in living cells which is
directionally proportional to the number of living cells in the culture. The absorbance
of the formazan at 490 nm was measured with a Genois ELISA spectrometer plate
reader. The experiments were performed in 5 replicates. Photographs of MRC-5 cells
were taken using a Nikon Eclipse TS100 microscope and analyzed on ImageJ.
Background subtraction was performed on the 8-bit grayscale images using a 30.0
pixel “rolling ball” algorithm. Thereafter image contrast was increased to delineate
cells from the background and the non-zero pixels belonging to cells were measured.
For each treatment, measurements from two different fields of vision were used for
Tukey’s Multiple Comparison test.
2.2.8 Confocal microscopy & TEM
To examine the uptake and distribution of the SiO2NP in MRC-5 cells, fluorescent
SiO2NP were synthesized using same synthesis procedure but doped with fluorescent
dye (Tris(2,2’-bipyridyl)dichlororuthenium(II) hexahydrate, Exmax=425 nm,
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Emmax=608 nm). MRC-5 cells were cultured on 18 mm diameter coverglass slips at
80,000 cells/well. After 24 h of culture and 24 h treatments with 0 (control), 10, 40
and 80 μg/mL of fluorescent SiO2NP respectively, cells were fixed with 2.5%
glutaraldehyde and washed thrice with PBS. The cover glass slips were subsequently
mounted onto microscope glass slides with the Gel Mount Aqueous Mounting Media
(Cat. No. G0918: Sigma-Aldrich). The fixed cells were imaged under a confocal laser
scanning microscopy (Olympus Fluorview 1000).
2.2.9 TEM examination of SiO2NP treated cells and EDX analysis (Energy-
dispersive X-ray Microanalysis)
MRC-5 lung fibroblast cells were cultured onto the LabTek 4 chambered glass cover
slips. After which, the cells were treated with different dose concentration of SiO2NP,
0 (control), 10, 40 and 100 μg/mL for 24 h. Following that, the media with SiO2NP
were removed and the cells were washed with PBS and fixed in 2.5% glutaldehyde
fixative for 1 h and later processed for TEM. Briefly, cells were post-fixed with 1%
osmium tetroxide followed by dehydration with an ascending series of alcohol before
embedding in araldite. Ultrathin sections were cut and doubly stained with uranyl
acetate and lead citrate. TEM specimens (without the double staining) were subjected
for elemental analysis with a CM120 BioTWIN electron microscope coupled with a
Philips EDAX microanalysis system.
2.2.10 TBARS assay
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MRC-5 lung fibroblasts were seeded at a density of 1 x 106 cells/ flask in T75 flasks.
One day after seeding, cells were washed once with PBS buffer then treated with 0
(control), 2.5 g/mL, 10 g/mL, 40 g/mL and 80 g/mL SiO2NP respectively. After
24 h treatment with SiO2NP, the cells were trypsinized and lysed with an
ultrasonicator. The samples were then prepared for the assay according to the assay
kit instructions (T-bars Assay Kit, Caymen Chemicals) and the final colorimetric
absorbance values were taken with a plate photospectrometer at an absorbance
wavelength of 540 nm. The experiments were performed in triplicates.
2.2.11 Statistical analysis
IBM SPSS Statistics 19 was used to perform the tests and create boxplots for Fig 4A.
Graphs for cell area, MTS & TBARS assays were created and analyzed using
GraphPad Prism 5. Tukey's Multiple Comparison Test was used for analyzing three or




SiO2NPs were synthesized using the reverse microemulsion method to achieve
nanoparticles with an average diameter of 45 nm. Dye-doped nanoparticles were
synthesized in a similar manner with the addition of RUPBY (Tris(2,2’-
48
bipyridyl)dichlororuthenium(II) hexahydrate). The fluorescence of the dye-doped
nanoparticles was measured using a PerkinElmer LS55 fluorescence spectrometer,
which showed the expected fluorescence with maximum excitation (Ex) at 425 nm
and maximum emission (Em) at 608 nm. Doped nanoparticles were of similar size to
that of uncoated SiO2NPs (Fig. 2.1).
Fig. 2.1 TEM images of SiO2NP (A) and fluorescent SiO2NP (B) are uniformly sized around
45 nm. Fluorescence spectrum (C) showed maximum excitation (EX) at 425 nm and
maximum emission (EM) at 608 nm.
2.3.2 MRC-5 cell line assay
The human fetal lung fibroblast MRC-5 cell line, a commonly used cell line for
studying respiratory diseases, was grown in 96-well culture plates at 4,000 cells/well
and treated with different doses of SiO2NP (0, 2.5, 10.0, 40.0, 80.0 µg/mL). Cell
viability was tested using the MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) assay and the cell
morphology assessed visually under light microscopy. The treatment did not result in
any significant decrease in viability or changes in cell morphology for all doses
studied (Fig. 2.2). The mean area occupied by cells are generally similar (Fig. 2.2C).
A minor dip is observed at 10µg/mL, but this is likely due to both chance & scaling of
the chart’s y-axis. We proceeded to prepare samples for the metabolomics study by
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treating MRC-5 cells with non-doped SiO2NP of different concentrations (0 to 80
g/mL) for 24 hours. After treatment, cells were washed with ice cold phosphate
buffered saline, scraped and immediately quenched in liquid nitrogen. Samples were
lyophilized and extracted for their metabolites using methanol spiked with an internal
standard. Sample extracts were analyzed using GC-MS and LC-MS and the acquired
spectral data were pre-processed using MZmine 2.0 (Pluskal et al., 2010). This was
followed by multivariate analysis using OPLS-DA (orthogonal projections to latent
structures discriminant analysis (Bylesj et al., 2006)) to discover differences between
metabolic profiles of each treatment group. Among the myriad of metabolites detected,
a number of them are influential in distinguishing metabolic profiles of different
treatment groups.
2.3.3 Metabolomics findings
In the OPLS-DA model, these metabolites were assessed for their influence on inter-
group separation using their VIP value (variable importance in the projection). A VIP
value of >1.0 indicates that the metabolite has a strong influence. Kruskal-Wallis test
was further performed on this metabolite to assess for statistical significance between
different doses. In general, only metabolites with a VIP>1.0 and p<0.05 were
identified using reference spectral data from National Institute of Standards and
Technology (for GC-MS data) and Human Metabolome Database (for LC-MS data).
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Fig. 2.2 Morphological examination and MTS assay for cell viability. MRC-5 cells were
incubated with different concentrations of SiO2NP, 0 (control), 2.5, 10, 40 and 80 μg/mL for
24 h. The images in (A) showed no apparent morphological changes and this was supported
by no statistically significant changes observed for (B) the MTS cell viability assays (mean ±
SEM (n=5)) and (C) area occupied by cells (mean ± SEM (n=2)) measured using ImageJ.




In Fig. 2.3A and 2.4A, the OPLS-DA models of GC-MS and LC-MS data show
separations of different treatment groups with good predictive parameters (GC-MS:
R2X=0.420, R2Y=0.858 and Q2(cumulative)=0.727; LC-MS: R2X=0.374, R2Y=0.988
and Q2(cumulative)=0.607).  Underlying the separations are the major metabolites
demonstrated in the heatmaps (Fig. 2.3B and 2.4B). In Fig. 2.3B, we noticed a trend
where cellular amino acids were downregulated and on the contrary, urea was
upregulated with increasing doses of SiO2NP.
Fig. 2.3 (A) OPLS-DA plot for GC-MS data. (B) Metabolites changes detected using GC-
MS. MRC-5 cells (4 parallel sets of samples) were treated with different concentrations of
















In the list of detected LC-MS metabolites (Fig. 2.4B), the effect of SiO2NPs treatment
resulted in higher levels of lysophosphatidylcholine & -ethanolamine (LPC and LPE).
Glutathione (GSH) was further observed to be decreased (Fig. 2.5A). As GSH is an
important cellular antioxidant, we sought to determine if cellular oxidative damage
occurred using the TBARS assay. This assay measures malondialdehyde (MDA), a
by-product from lipid peroxidation caused by oxidative stress (Yagi, 1998). The
TBARS assay affirmed the presence of oxidative stress as the MDA level rose along
with increased SiO2NP doses (Fig. 2.5B).  This correlation further confirmed that
oxidative stress is one of the major toxic effects of SiO2NP.
Fig. 2.4 (A) OPLS-DA plot for LC-MS data. (B) Metabolites changes detected using LC-
MS. MRC-5 cells (4 parallel sets of samples) were treated with different concentrations of













2.3.4 Electron microscopy reveals uptake of SiO2NP in vacuoles
Although the metabolomics data clearly showed dose-dependent changes of
metabolites, including various amino acids and phospholipids, we did not observe any
cellular morphological changes or differences in cell viability upon treatment with
SiO2NP.  Therefore, in order to explore plausible causes for such endogenous
metabolite shifts, we assessed SiO2NP uptake in MRC-5 cells using doped-SiO2NP
under confocal microscopy. In Fig. 2.6, increasing uptake of SiO2NP by cells was
observed as indicated by the increase of fluorescence intensities, despite no overt
morphological changes to the cells.
Fig. 2.5A LC-MS measurement of glutathione (GSH) levels in response to silica NP
dose. The GSH levels decreased with increasing doses of silica NP, reflecting its gradual
utilization against oxidative stress caused by the NPs (* indicates p < 0.05 when tested




Fig. 2.5B TBARS assay reflected as MDA concentration. MRC-5 cells were treated with
different concentrations of SiO2NP, 0 (control), 2.5, 10, 40 and 80 μg/mL for 24 h. (* indicates
p < 0.05). Data were presented as mean±SEM (N=3). Statistical analysis was performed
using Tukey's Multiple Comparison Test.
Examination of the cells with the same treatment conditions under transmission
electron microscopy (TEM) revealed that vacuoles of MRC-5 cells increased in
number and size in a dose-dependent manner (Fig. 2.7). The particulate matter
engulfed by vacuoles was further confirmed to be SiO2NP using energy dispersive X-
ray (EDX) microanalysis. It is known that endocytosis appears to be a main route for
nanoparticle uptake and we hypothesize that the increased rate of endocytosis and
formation of multiple large vacuoles could have affected cellular energetic demands,
thereby affecting the proper metabolism of cells. As can be seen in Fig. 2.7, SiO2NPs
could be found in the proximity of mitochondria, suggesting that SiO2NPs may affect
mitochondrial function, and in turn induced disturbances in the metabolism processes
of the Krebs cycle.
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Fig. 2.6 Confocal microscopy images of MRC-5 lung fibroblast cells. (A) Untreated cells
as control and cells treated with 2.5, 10, 40 and 80 µg/mL fluorescent SiO2NP (B-E)
respectively.
Fig. 2.7 TEM images of ultrathin sections of MRC-5 cells. MRC-5 cells were treated with
different concentrations of SiO2NP, 0 (control), 10, 40 and 80 μg/mL for 24 h. N refers to
nucleus and M refers to mitochondrion. SiO2NP are indicated by red arrows and the EDX
profile of the particles found within vacuoles is shown in lower right. The dense clusters of
NPs were identified as silica as evidenced by the Si peak. Specimens were mounted on
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nickel grids and an osmium peak as the specimens were osmified with osmium tetroxide,
hence accounting for the Ni and Os peaks. Scale bar was set 2 μm for “a” and 0.2 μm for “b”.
2.4 Discussion
Metabolomics is a relatively new technology that analyses samples based on their
metabolic profiles. It was hypothesized that SiO2NPs could have toxicity effects on
MRC-5 cells and here we applied metabolomics to reveal effects that complemented
morphological observations and cell viability tests.
The initial morphological observations and cell viability did not indicate any adverse
effects of SiO2NPs on the cells. Further investigations with metabolomics revealed
perturbations in the amino acid and lipid metabolism, together with an increase in
oxidative stress. As we explored plausible causes for such perturbation, confocal
microscopy showed dose-dependent uptake of SiO2NPs, while electron microscopy
showed increased vacuolization and engulfment of SiO2NPs.
In terms of amino acid metabolism, amino acids were observed to decrease with
increasing SiO2NPs doses. On the contrary, urea was increasing. This seems to
suggest that active deamination, which is intimately related to decreasing amino acid
levels, could have taken place in the cells when exposed to SiO2NPs. Aspartate (Asp)
is a pivotal amino acid in the cellular deamination pathway, and is an NH2- group
carrier. The decreasing level of Asp may hence be closely related to increased urea
production. As a consequence of decreased amino acids and increased urea levels,
proper cellular function could have been affected. Apart from deamination, various
amino acids such as isoleucine and threonine are also related to energy production
through glucogenic and/or ketogenic mechanisms. Through these two processes,
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amino acids could be channeled into the Krebs cycle by being converted into suitable
substrates such as pyruvate, acetyl-CoA or Krebs cycle intermediates for energy
production.
Other metabolic effects observed were related to lipids and GSH. LPC and LPE are
lipids observed to be increased with increasing SiO2NPs doses and they have been
postulated to be biomarkers of biochemical injury arising from cellular  toxicity (Cox
& Cachón-González, 2012). GSH was found to be decreased with increased SiO2NPs
doses and this corroborates well with an increase in MDA, an oxidative stress
indicator (Fig. 2.5B). Together, these two findings further confirmed that oxidative
stress is one of the major toxic effects of SiO2NP
The reason for SiO2NP induced cellular vacuolization is at present not clear, but it is
believed to be highly dependent on nanoparticle size in which our SiO2NPs appear to
be well-sized for endocytosis at 45 nm diameter width (Chithrani, Ghazani, & Chan,
2006; S. Zhang, Li, Lykotrafitis, Bao, & Suresh, 2009). The parallel increase of
vacuoles as observed in Fig. 2.7 and the increase of cellular LPC and LPE detected
using LC-MS (Fig. 2.4B) are likely to be closely associated since both phospholipids
are the main components of vacuole membrane. In an earlier study, gold nanoparticles
were found to induce autophagy with a concomitant change in oxidative stress in
MRC-5 lung fibroblasts (Li, Hartono, Ong, Bay, & Yung, 2010). From our study, the
perturbed metabolism lowers the availability of amino acids and GSH, which may
present a cellular state of reduced nutrients and increased oxidative stress that may
induce autophagy (Rabinowitz & White, 2010). Under such circumstances, there may
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be a close association between vacuolization and autophagy, when MRC-5 cells are
exposed to nanoparticles.
2.5 Conclusion
Our metabolomics-based study integrates two highly sensitive and complementary
chromatographic mass spectrometry platforms to discover metabolic perturbations.
With these platforms, we detected significant and dose-dependent changes in the
metabolic profiles of human MRC-5 fetal lung fibroblasts that were treated with
different doses of SiO2NPs. Our results revealed that despite no evidence of
morphological or viability changes, there was already a decrease of various cellular
amino acid levels accompanied by increased urea and phospholipid concentrations.
Glutathione, an important cellular antioxidant was also decreased in a similar dose-
dependent manner.  Further examinations revealed increases in cellular vacuole size
and number, with increasing SiO2NP concentration. Our work therefore brings forth a
new aspect of nanotoxicity where metabolomic changes are associated with increased
SiO2NP doses, most likely due to oxidative stress. The above findings have provided
a better biological insight of the molecular mechanism by which SiO2NPs affect lung
cells.
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Chapter Three
Use of Zebrafish Embryos and
Metabolomics to Assess Water Quality
Part of this work has been published in Molecular Biosystems (2013)
Huang SM, Xu F, Lam SH, Gong Z, Ong CN. Metabolomics of developing zebrafish
embryos using gas chromatography- and liquid chromatography-mass spectrometry.
Molecular Biosystems. 2013 Jun;9(6):1372-80
60
Project Abstract
Rationale: The zebrafish is an increasingly popular animal model for biomedical and
environmental research. This is due to its genetic similarity to humans, low husbandry
cost and its ability to spawn eggs in large quantities. Their eggs are particularly
valuable for toxicity testing because they are sensitive to chemicals. During the first
48 hours post fertilization (hpf), the embryo develops rapidly into a larva while
remaining optically transparent. Such transparency facilitates the monitoring of
morphological effects. Hence by using these transparent embryos in large quantities,
researchers can quickly characterize toxicity effects with ease and statistical
robustness. Zebrafish embryos have been used to evaluate water quality and
conventionally, assessment of toxicity effects still relies on visual observation. We
believe more biological insights can be derived through molecular profiling
techniques.
Hypothesis 1: We hypothesize that during zebrafish embryogenesis, the metabolic
profiles of the embryos change as they transition from embryo to larva.
Hypothesis 2: The exposure of embryos to toxic chemicals during their growth can
induce perturbations of the metabolic pathways. If no discernible morphological
effects can be observed, metabolomics may reveal the impact of chemical exposure at
the metabolic level.
Objective and Methods: The first objective is thus to measure the temporal profiles
of metabolites during embryogenesis and identify key characteristic changes.
Zebrafish embryos were sampled at key junctures of their embryogenesis (4, 8, 12, 24,
48 hpf) and profiled using metabolomics. Multivariate and univariate analyses were
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applied to the acquired raw data to shortlist metabolites with significant changes for
identification. Publicly available transcriptomics data were used to supplement the
metabolomics findings. The second objective is to determine if metabolic pathways
can be perturbed by the exposure of embryos to toxic chemicals. Here we used N-
nitrosodimethylamine (NDMA), a toxic by-product commonly found in treated
drinking water, as a known toxin to test our hypothesis. Embryos were exposed to low
doses of NDMA (control, 0.1, 1, 10µg/L) to test the feasibility of detecting effects
using metabolomics.
Measurements and Main Results: Metabolic profiles were markedly different at
different stages of embryogenesis. Interestingly, more unique metabolites were
detected in later stages of development. The 48hpf stage was found to have the most
unique number of metabolites and this time point could be suitable for monitoring
perturbations caused by the toxicant.
During the exposure of embryos to NDMA, there was no significant mortality nor
morphological effects across all tested doses. However, metabolomics revealed dose-
dependent effects at the metabolic pathway level, particularly for the amino acid, lipid
and oxidative stress pathways.
Conclusions: The zebrafish embryos are a promising testing model that can facilitate
toxicological investigations with untargeted metabolomics. In the present study,
although morphological observations provided no observable effects, metabolomics






The zebrafish is an increasingly popular vertebrate model and it offers many
advantages compared to rodent models. The reasons for its rising popularity include
its genetic relevance to humans, low cost of animal husbandry and potential for high-
throughput studies (Lieschke & Currie, 2007). Indeed, zebrafish embryos are readily
available in large numbers (around 400 eggs per breeding pair) and they develop
rapidly into larvae within 48 hours and are also sensitive to chemical treatment (Nagel,
2002). So far, omics studies of early zebrafish development have been mainly focused
on proteomics (Y. Lin, Chen, Yang, Xu, & Liang, 2009; Link, Shevchenko, &
Heisenberg, 2006; Tay et al., 2006) and transcriptomics (Aanes et al., 2011; Mathavan
et al., 2005) of zebrafish embryogenesis. A comprehensive analysis of metabolomics
of early zebrafish development will be a necessary complement for a holistic view of
embryogenesis of not only a fish model but also the early development as a whole.
Metabolomics is the systemic and comprehensive analysis of metabolites in a
biological sample/system where differential metabolic profiles can potentially point
towards the effect of a stimuli/biological process and also the toxicity of a chemical.
The instruments predominantly used in metabolomics are the nuclear magnetic
resonance (NMR) spectroscopy, gas chromatography- & liquid chromatography-mass
spectrometry (GC-MS & LC-MS). For the detection of low abundance metabolites,
GC-MS & LC-MS are commonly used due to its higher sensitivity. This instrumental
setup also allows for multiple sample analysis in a rapid manner compared to NMR
where sample automation is less efficient than GC-MS & LC-MS.
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In this study, we used both GC-MS and LC-MS to elucidate metabolite profile
changes occurring in developing zebrafish embryos at 4, 8, 12, 24 and 48 hours post
fertilization (hpf). The use of these five time points provides a snapshot of metabolic
profiles of five key developmental stages of the embryo, namely the blastula (2¼ - 5¼
hpf),  gastrula (5¼ - 10 hpf), segmentation (10-24 hpf), pharyngula (24-48hpf) and
hatching period (48-72 hpf) (Kimmel, Ballard, Kimmel, Ullmann, & Schilling, 1995).
As this study focuses solely on embryos, hatched larvae were not used. Previous
studies have been performed to understand the metabolomics of zebrafish
embryogenesis and they were performed using only GC-MS (Hayashi, Yoshida,
Fujiwara, Maegawa, & Fukusaki, 2011), LC-MS (Hayashi et al., 2011; Papan & Chen,
2009) or a combination of LC-MS with NMR (Soanes et al., 2011). Our work here
aims to identify a broader spectrum of metabolites using GC-MS and LC-MS along
with higher sensitivity. As a proof of concept for the latter aim, we further test the
feasibility of zebrafish metabolomics for toxicity testing using N-
nitrosodimethylamine (NDMA). NDMA is a water disinfection by-product and based
on World Health Organization (WHO) guidelines, 0.1µg/L is deemed as the cut-off
exposure value for drinking water (WHO, 2008).
3.2 Materials and methods
3.2.1 Collection procedure
Wild-type zebrafish eggs were collected from the aquarium in the Department of
Biological Sciences, National University of Singapore. The use of zebrafish embryos
was approved under the Institutional Animal Care and Use Committee (IACUC) of
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National University of Singapore (Protocol 081/10). Embryos were maintained in egg
water with daily change of the solution.  Temperature was maintained at 28.5°C
throughout embryogenesis. Embryos that were non-viable or developed abnormally
were excluded. Five sets of 50 embryos (per set) were collected at each time point (4,
8, 12, 24, 48 hpf) and washed twice with egg water to remove residual contaminants.
All five sets of embryos were snap-frozen in liquid nitrogen to quench metabolism.
They were subsequently freeze-dried overnight for 16 hours.
For the pilot study on toxicity testing, zebrafish embryos were treated with NDMA
from 2.5hpf to 48hpf using doses of 0, 0.1, 1, 10µg/L. Briefly, each treatment group
consists of five replicates (30 embryos each). At 48hpf, 15 viable embryos were
randomly sampled and snap-frozen in liquid nitrogen. All doses and control contain
DMSO as it was used to dissolve NDMA prior to serial dilution. The solutions were
changed at 24hpf to maintain water quality.
3.2.2 Extraction
Methanol was chosen as the extraction solvent and 10 μg/ml of Fmoc-glycine was
added in as an internal standard. In the first part of the study (embryogenesis
metabolomics), 350 µl of methanol was added to each sample tube containing 50
lyophilized embryos and vortexed for 3 min. Subsequently, the tubes were sonicated
for 15 min at 4°C to enhance metabolite extraction. The resultant suspension was
centrifuged for 10 min at 16.1 rcf and its supernatant was centrifuged again under
exact conditions to remove solid remnants. 100 µl of the supernatant was directly
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used for LC-MS analysis, while another 100 µl was chemically derivatized with
methoxyamine (50 µg/mL in pyridine, 37°C×2 h) and followed by 200µL of MSTFA
(37°C×16 h) prior to GC-MS analysis as previously reported (Ng et al., 2012b).
The same method was applied to the second part of the study (NDMA) with a minor
modification. Each tube contained 15 embryos, hence the volume of methanol was
adjusted to 100 µl. 20 µl of supernatant was used for direct LC-MS analysis and
another 20 µl was chemically derivatized as described above.
3.2.3 GC-MS and LC-MS analysis
For the embryogenesis study, derivatized samples (1.0 µL) were injected splitlessly
with an Agilent 7683 Series autosampler into an Agilent 6890 GC system equipped
with a fused-silica capillary column HP-5MSI (30 m × 0.25 mm i.d., 0.25 µm film
thickness). The inlet temperature was set at 250°C. Helium was used as the carrier gas
at a constant flow rate of 1.0 mL/min. The column temperature was initially
maintained at 70°C for 1 min, and then increased to 250°C at a rate of 10°C /min and
further increased at 25°C/min to 300°C where it remained for 5 min. The column
effluent was introduced into the ion source of an Agilent Mass selective detector. The
transfer line temperature was set at 280°C and the ion source temperature at 230°C.
The mass spectrometer was operated in electron impact (EI) mode (70eV). Data
acquisition was performed in full scan mode from m/z 50-550 with a scan time of 0.5s.
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LC-MS analysis was performed on an Agilent 1200 HPLC system (Waldbronn,
Germany) equipped with 6410 QQQ triple quadrupole mass detector and managed by
a MassHunter workstation. The column used for the separation was an Agilent rapid
resolution HT Zorbax SB-C18 (2.1 × 50 mm, 1.8µm) (Agilent Technologies, Santa
Clara, CA). The oven temperature was set at 50°C. The gradient elution involved a
mobile phase consisting of (A) 0.1% formic acid in water and (B) 0.1% formic acid in
methanol. The initial condition was set at 5% of B. The following solvent gradient
was applied: from 95% A and 5% B to 10% A and 90% B within 10 min, hold for 10
min and then to 100% B within 5 min and hold for 10 min. Flow rate was set at 0.2
ml/min and 5µl of samples were injected.  The ESI-MS were acquired in positive and
negative ion mode, respectively. The ion spray voltage was set at 3,000 V. The heated
capillary temperature was maintained at 350°C.  The drying gas and nebulizer
nitrogen gas flow rates were 10 L/min and 30 psi, respectively. For full scan mode
analysis spectra were stored from m/z 100 to 1000.
The pilot study on NDMA exposure was performed on a different set of instruments.
LC-MS analysis was performed on an Agilent 1290 UHPLC system (Waldbronn,
Germany) coupled to 6540 quadrupole-time of flight (Q-TOF) mass detector equipped
with a dual jet stream electrospray ionization source and managed by a MassHunter
workstation. The column used for the separation was an Agilent rapid resolution HT
zorbax SB-C18 (2.1 × 50 mm, 1.8 µm). The oven temperature was maintained at
50°C. The gradient elution involved a mobile phase consisting of (A) 0.1% formic
acid in water and (B) 0.1% formic acid in methanol. The initial condition was set at 5%
of B. The following solvent gradient was applied: from 5% B to 90% B within 5 min,
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hold for 2.5 min and then to 100% B within 2.5 min and hold for 4 min. Flow rate was
set at 0.4 mL/min and 5 µL of samples was injected. The electrospray ionization-mass
spectrometry (ESI-MS) was acquired in positive mode. The ion spray voltage and
nozzle voltage were set at 4,000 V and 1,000 V, respectively. The drying gas and
sheath gas temperatures were maintained at 325°C and 350°C, respectively. The
drying gas and sheath gas flow rates were 10 L/min and 12 L/min, respectively. The
nebulizer nitrogen gas flow rate was set at 55 psi. For full scan mode analysis spectra
were stored from m/z 101 to 1,400 in centroid mode.
For GC-MS, it was performed on an Agilent 7683B series injector coupled to an
Agilent 7890A series gas chromatography system and a 7200 Q-TOF mass
spectrometry. Separation was performed on a fused-silica capillary column HP-5MSI
(30 m × 0.25 mm i.d., 0.25 µm film thickness). The inlet temperature was set at
250 °C. A 1 μL of sample was splitless injected for each individual analysis. Helium
was used as the carrier gas with a constant flow rate at 1 mL/min through the column.
The GC oven temperature was maintained at 70 °C for 1 min, and then increased to
250 °C at a rate of 10 °C/min and further increased at 25 °C/min to 300 °C and hold
for 6 min. The total running time was 27 min. The transfer line temperature was set at
280 °C. Detection was achieved using MS in EI mode (70 eV) and full scan
monitoring (m/z 50 to 550). The temperatures of ion source and quadrupole were set
at 230 °C and 150 °C, respectively. The solvent delayed time was set as 4.1 min.
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3.2.4 Mass spectrometry data pretreatment, marker metabolites selection and
identification
Each chromatogram obtained from GC-MS and LC-MS analysis was pre-processed
using MZmine 2.0 (Pluskal et al., 2010) to generate discrete peak lists containing m/z,
retention time (RT) and ion abundance (peak intensity). The data were combined into
a single matrix by aligning peaks with the same m/z and RT for GC-MS and LC-MS
data, respectively. The area of each peak was normalized to that of internal standard
(FMOC-glycine) in each data set. The data was subsequently filtered by the presence
of peaks in at least 80% of one sample category (Bijlsma et al., 2006).
The pre-processed GC-MS and LC-MS data were exported to SIMCA-P 11.0
(Umetrics AB, Umeå, Sweden) for analysis and visualization by multivariate
statistical methods. Two multivariate analysis methods were used to find the optimal
separation of clusters, namely the principal component analysis (PCA) and orthogonal
projection to latent structure-discriminant analysis (OPLS-DA). For PCA & OPLS-
DA, all data were mean-centered and unit variance scaled. A 7-fold cross-validation
was applied to both PCA & OPLS-DA.
The variable importance in the projection (VIP) values reflect the importance of terms
in the OPLS-DA model both with respect to Y, i.e. its correlation to all the responses,
and with respect to X (the projection). Thus, metabolites with VIP value greater than
one were selected for further test and validation using Kruskal-Wallis Test (p < 0.05).
The selected compounds from GC-MS analysis were identified by comparison of
mass spectra and retention time with those of reference standards, and those available
in libraries (NIST 2005), While those from LC-MS detection were searched in the
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Human Metabolome Database (HMDB, www.hmdb.ca) first using ion mass and then
were further identified by either MS/MS fragmentation pattern or reference standards
(Xu, Zou, Lin, & Ong, 2009).
Heatmaps of identified metabolites were generated using MultiExperiment View
Version 4.8 (Saeed et al., 2006) and further analyzed using agglomerative hierarchical
cluster analysis based on Pearson correlation distances with gene leaf optimization.
The Kruskal-Wallis Test was also performed within this software package. Further
details can be found in the Supplementary Information 1.
3.2.5 mRNA transcript matching with target metabolite
The dataset 3 from Mathavan et al (Mathavan et al., 2005) represents all detectable
mRNA with regulation during development and all transcripts were analyzed for their
gene ontologies (GO) and KEGG pathways. The software GeneCodis (Nogales-
Cadenas et al., 2009) and WebGestalt (B. Zhang, Kirov, & Snoddy, 2005) were used
to discover the GO and KEGG annotations and the results were manually interpreted
for relevance to metabolism. Transcripts of enzymes that were directly catalyzing
reactions leading to or converting the target metabolite were shortlisted and plotted
alongside the metabolite levels against developmental time. The dataset 3 is publicly
available at (http://giscompute.gis.a-
star.edu.sg/~govind/zebrafish/data_download.html). Proteomic data from Tay et al




3.3.1 Clustering of metabolomic data shows changes during embryogenesis
PCA was used to separate data in both the GC-MS and LC-MS data without a priori
knowledge of time points (Fig. 3.1A & 3.1C). Generally, ‘early’ development
metabolomes (4, 8, 12 hpf) can be distinguished from the 24 & 48 hpf metabolomes.
Together with loadings plots (Fig 3.2), we were able to observe the relationships of
clusters to the identified metabolites. To further improve upon the resolution of
clusters, OPLS-DA was performed.
Data obtained from GC-MS were used to construct an OPLS-DA model (Fig. 3.1B),
which showed performance statistics of R2X=0.585, R2Y=0.985 and Q2 (cum)=0.940.
Five time points namely 4 hpf, 8 hpf, 12 hpf, 24 hpf and 48 hpf, were separated into
five distinct clusters with little overlap. Analysis of OPLS-DA loadings and variable
importance in the projection plot (VIP) values indicated several discriminatory
metabolites that differentiated between the five groups. In the present study, only
metabolites with VIP>1.0 were included in the final data analysis. Kruskal-Wallis test
(p<0.05) was employed to select metabolites that dominated the overall separation
between different developmental time points. Data obtained from LC-MS were used
to construct an OPLS-DA model (Fig. 3.1D), which showed performance statistics of
R2X=0.390, R2Y=0.987. The five time points separated very well with a high
prediction parameter Q2 (cum) of 0.894. Metabolites were also selected via the same
statistical methods used for GC-MS data.
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Fig. 3.1 Multivariate analysis of the time-dependent metabolomic changes in zebrafish
embryogenesis. A direct comparison between PCA analyses (A and C) and OPLS-DA (B and D)
analyses demonstrates that OPLS-DA resolves the observations into 5 clusters instead of 3 clusters
shown in PCA. The Q2 values were also improved using OPLS-DA in place of PCA. The
components t1 andt2 are reflected on the horizontal and vertical axis respectively.
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Fig 3.2 PCA loadings plot of GC-MS (top) and LC-MS (bottom) data derived from
zebrafish embryogenesis samples (see Fig. 1). The horizontal axis refers to the first
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3.3.2 Hierarchical clustering analysis and identification of metabolites
For GC-MS analysis, 53 peaks were statistically shown to be crucial towards the
segregation of developmental time points and 20 of them were successfully identified
through the NIST library. The use of hierarchical clustering analysis (HCA) classified
metabolites into clusters of different regulatory trends. Most of the metabolites show
an increase as developmental time progressed with the exception of hypoxanthine,
isocitrate, myo-inositol and cholesterol Fig. 3.3, above). The most conspicuous
change was observed for the amino acids, where they were all increased along with
developmental time. LC-MS uses a reversed phase column and is complementary to
GC-MS, hence a largely different set of metabolites were identified. Among the 40
identified metabolites (Fig. 3.3), the majority consisted of phosphatidylcholines (PC)
and lysophosphatidylcholines (LPC) of different carbon chain lengths. Some of these
lipids were downregulated over time, suggesting a catabolic role for these lipids,
whereas some were increasingly upregulated as development progressed. Amino acids
and related substances (gluthatione, betaine, creatine) were similarly upregulated as
reflected in the GC-MS data, showing a consistent trend between both methods. A
small overlap of five metabolites was found between GC-MS & LC-MS data and
exhibited the same trend.
The “variable importance in the projection” (VIP) values of an OPLS-DA model
describe the importance of a metabolite in distinguishing different time points (Table
3.1). Here we observe that many amino acids were able to discriminate time points,
with notable examples of tyrosine, methionine and branched-chain amino acids
(isoleucine, leucine and valine). Hypoxanthine was also notably ranked with a high
75
score in both GC-MS (VIP=1.69) and LC-MS (VIP=2.40) data. Some metabolites
were detected in both GC-MS and LC-MS experiments and found to have the same
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general trend. These metabolites are proline, 5-oxoproline, hypoxanthine,
phenylalanine and tyrosine. Though mild intensity variations occurred for proline and
Fig. 3 Heatmaps of identified metabolites. Hierarchical clustering analysis (HCA) was performed on
identified metabolites using Pearson correlation as the distance metric. From the regulatory trends in the
heatmap, it is observed that amino acids were the main upregulated components, whereas nucleobases
and lipid metabolites were downregulated. A subset of lipids, namely phosphocholines displayed a varied
regulation.
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5-oxoproline in LC-MS data, the general trend of these two metabolites shows that
they increase over time and demonstrate the consistency of results between the two
metabolomic platforms.
Table 3.1 The variable importance in the projection (VIP) values of identified
metabolites. Higher values indicate a stronger influence of the metabolite in
distinguishing different time points.
GC-MS LC-MS




Tyrosine 1.75 Hypoxanthine 2.40 PC(38:6) 1.55
L-methionine 1.71 Phenylalanine 2.32 PC(42:9) 1.51
Hypoxanthine 1.69 Histidine 2.22 PC(32:3) 1.41
L-valine 1.68 Tyrosine 2.19 LPC(18:1) 1.37
Iso-leucine 1.66 Creatine 2.06 LPC(16:1) 1.36
Leucine 1.59 Betaine 1.99 LPC(20:5) 1.35
Urea 1.59 LPC(20:1) 1.93 PC(40:8) 1.33
L-threonine 1.58 PC(36:4) 1.89 LPC(18:0) 1.32
L-phenylalanine 1.57 PC(32:0) 1.88 Proline 1.31
Mannose 1.53 Carnitine 1.86 PC(38:4) 1.24
Galactopyranose 1.52 LPC(18:0e) 1.83 5-oxoproline 1.23
Pyroglutamic acid 1.52 PC(40:6) 1.81 LPC(18:2) 1.16
L-proline 1.42 Tryptophan 1.79 PC(38:5) 1.11
Isocitric acid 1.41 LPC(20:4) 1.76 PC(36:6) 1.04
D-glucose 1.25 PC(42:7) 1.75 Glutathione 1.02
Glutamic acid 1.23 PC(36:6) 1.72 PC(44:12) 1.01
Alpha-tocopherol 1.20 LPC(20:2) 1.64 PC(36:3) 1.01
Serine 1.15 PC(37:5) 1.63 PC(35:5) 1.01
Cholesterol 1.12 PC(36:7) 1.62
Myo-inositol 1.09 PC(34:0) 1.59
3.3.3 Linking metabolite levels to gene expression levels
An attempt was further made to determine if enzymes related to these detected
metabolites are similarly regulated during development. Thus, we analyzed the
mRNA transcript levels of related enzymes from Mathavan et al (Mathavan et al.,
2005) to find associations. Based on the list of regulated transcripts, gene ontologies
and KEGG pathways of the transcripts were determined and manually interpreted for
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relevance to our metabolites. We found 15 metabolite-transcript associations (Table
3.2) and among them, three appeared to have important nutritional and antioxidative
roles in embryogenesis. There are correlations between amino acids and cathepsins,
hypoxanthine and hprt1 and lastly glutathione and a modifier subunit that affects its
synthesis (Fig. 3.4). Cathepsin L is thought to be the key enzyme involved in
vitellogenin utilization and based on transcriptomic data, the cathepsin L-a is
expressed differentially throughout embryogenesis. The L-a isoform has a high initial
expression which decreases as embryogenesis proceeds. It has been shown by whole
mount in situ hybridization that cathepsin L-a is expressed in the yolk syncytial layer
(YSL) and is postulated to be the main yolk processing enzyme (Tingaud-Sequeira &
Cerdà, 2007). With increased cathepsin to process vitellogenin, we observe a
corresponding rise in all amino acids detected (Fig 3.4A-C). Cathepsin D and
Zgc:85774 (also known as Cathepsin H) are other isoforms found to be possibly
involved in yolk processing. For cathepsin D, it has been shown to be a putative yolk
processing enzyme in rainbow trouts (Kwon, Prat, Randall, & Tyler, 2001). Its
expression surges up after 8hpf to reach a peak around 24hpf. Zgc:85774 is a
relatively uncharacterized isoform but from its stark  fold change, it may be a likely
mediator in yolk processing.
Table 3.2 Detectable metabolite-transcript associations for embryogenesis
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Metabolite Transcript match Reaction
Valine  Branched chain
aminotransferase 2,
mitochondrial
Branched chain amino acid + 2-
oxoglutarate corresponding
keto acid + L-glutamate
Leucine  Branched chain
aminotransferase 2,
mitochondrial
Branched chain amino acid + 2-
oxoglutarate corresponding
keto acid + L-glutamate
Isoleucine  Branched chain
aminotransferase 2,
mitochondrial
Branched chain amino acid + 2-
oxoglutarate corresponding
keto acid + L-glutamate





 L-serine + L-homocysteine
 L-cystathionine +
H2O





from methionine and ATP
Glutamic acid  Glutamate-cysteine ligase,
modifier subunit
 Glutamate dehydrogenase 1a
 Glutamate-ammonia ligase
(glutamine synthase) a
 Rate limiting step in
glutathione synthesis
 Oxidative deamination of
glutamate to 2-oxoglutarate
and free NH4+ using either
NAD+ or NADP+ as a co-
factor
 Glutamate + ATP + NH3 →
Glutamine + ADP +
phosphate
Phenylalanine  Wu:fe50f06  Phenylalanine-tRNA ligase
activity
Hypoxanthine  Hypoxanthine guanine
phosphoribosyltransferase-
like
 conversion of hypoxanthine
to inosine monophosphate
and guanine to guanosine
monophosphate.
Tyrosine  Tyrosine hydroxylase  L-tyrosine to L-3,4-
dihydroxyphenylalanine (L-
DOPA).






including that of vitellogenin
(for all cathepsins, including
Zgc:85774)
80
Hypoxanthine is a precursor in purine synthesis pathway and is salvaged to inositol
monophosphate via hypoxanthine-guanine phosphoribosyltransferase (hprt1). A sharp
decline in hypoxanthine levels occurred from 8 to 24 hpf, indicating a possible
utilization of hypoxanthine towards purine & nucleotide synthesis. By 24 hpf,
hypoxanthine levels were only present at detection baseline. Correspondingly, the
hprt1transcript peaked briefly at 4 hpf & 12 hpf and gradually diminishing by 48 hpf,
where hypoxanthine levels were at detection baseline.
Glutathione synthesis involves glutamate-cysteine ligase (GCL) and it synthesizes an
intermediate called gamma-glutamylcysteine (GGC), before it is converted to
Fig. 3.4 Metabolites and mRNA relationships. (A–D) The abundance of detected amino
acids and relation to cathepsin-L. Amino acids increase over the span of embryogenesis and it
is likely to be mediated by the increased mRNA transcription of cathepsin-L enzymes that
degrade vitellogenin. (E–F) Relationship between hypoxanthine, glutathione and their
associated mRNA transcripts. The levels of hypoxanthine and glutathione are related to the
enzyme transcripts that modulate them. Hprt1 converts hypoxanthine into nucleotide precursors
such as inosine monophosphate and guanine, while the modifier subunit of glutamate-
cysteine ligase increases the synthesis of glutathione. Solid lines are metabolomic data while
dotted lines are transcriptomic data. Mean (±SD) values were plotted for metabolites, whereas
mean values are given for transcript log2 ratios.
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glutathione. We observed the upregulation of GCL’s modifier subunit (at 12 hpf),
which controls the enzyme’s catalytic efficiency and hence increase production of
GGC which is a precursor for glutathione.
Studies also show that regulation of GSH synthesis is greatly affected by GCL
(Guoyao Wu, Fang, Yang, Lupton, & Turner, 2004) and therefore upregulating the
modifier subunit would likely increase GSH synthesis. More enzyme-metabolite
associations are presented in the Table 3.2.
3.3.4 Linking proteomic data to metabolite levels
A previous report (Tay et al., 2006) showed the proteomic changes occurring during
zebrafish embryogenesis and establishing a direct relationship between actual enzyme
levels to metabolite levels may complement our work. The overabundance of
vitellogenin dominated much of the identified proteins and the data was analyzed on a
qualitative basis (absence/presence of protein). As shown in Table 3.3, we observed
close associations for two metabolites for glycolysis & tricarboxylic acid (TCA) cycle.
Table 3.3 Metabolite data related to enzymes regulated during embryogenesis (data







7 Glyceraldehyde 3-phosphate dehydrogenase Glucose, glycolysis 6–24








25 Triosephosphate isomerase 1a Glucose, glycolysis 6–24
16 Isocitrate dehydrogenase 3(NAD+) Isocitrate, TCA cycle 6–14
47 Aconitase 2 Isocitrate, TCA cycle 6–18
3.3.5 Proof of concept: Applying zebrafish metabolomics on embryos
exposed to NDMA
The results from zebrafish embryogenesis demonstrated metabolomics’ potential in
unravelling shifts of metabolic profiles. Having recognized this potential, we
envisioned using metabolomics as a complement to existing toxicology methods. As a
proof of concept, we exposed embryos to NDMA and sought to use metabolomics to
identify differential metabolites related to dose.
Embryos treated with NDMA up till 48hpf were assessed for morphological defects
and mortality. In general, no overt effects were observed for both defects and
mortality (Fig 3.5 A-B).  In contrast, metabolomics was able to reveal differential




Fig 3.5 Morphological effects and survival of embryos when exposed to NDMA. (A)
NDMA exposure (control, 0.1, 1, 10µg/L) does not significantly alter morphological features of
the larvae (48hpf). Typical abnormalities such as lack of pigmentation and unusual curvature





Multivariate analysis of LC-MS and GC-MS data using OPLS-DA was able to show
differential profiles related to dose treatment. In particular, the model built upon LC-
MS data has a higher Q² value than that of GC-MS, suggesting a better predictive
model. Based on the LC-MS OPLS-DA model, the effect of NDMA exposure begins
around 1µg/L and is strongest at 10µg/L, where a distinct cluster is observed (Fig 3.6,
right blue ellipse).
Beyond statistical models, the individual metabolites that are key to differentiating
dose effects were identified based on VIP >1 and p-value ≤ 0.05. Based on the
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Fig 3.6 Despite the lack of observable morphological features, multivariate analysis
(OPLS-DA) of the MS data reveals distinguishable profiles. The Q² value of the LC-MS
data model was relatively higher than that of GC-MS, suggesting that LC-MS data could
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doses are increased. The exceptions are acetylcarnitine and leucine which are
increased. Among the metabolites that decreased, two major metabolite classes can be
identified, namely the lipids and amino acids.  Another key effect is that of decreased
glutathione (GSH) levels. Collectively, the data suggests that NDMA exposure









Fig. 3.7 Heatmap and hierarchical clustering of differential metabolites related to
NDMA exposure. The classes of altered metabolites are generally the amino acids and
lipids. They are observed to decrease as the NDMA dose increases. However, acetylcarnitine
& leucine are positively correlated with NDMA dose. Glutathione is decreased, suggesting
increased oxidative stress caused by NDMA.
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3.4 Discussion
Metabolomics is a high-throughput profiling method that generates a broad overview
of metabolic changes. It presents an opportunity for enhanced differentiation between
different biological states based on large datasets. We interpreted the data using two
different multivariate analysis methods namely PCA, and OPLS-DA, each with
successive improvements on separation of clusters. Through the use of OPLS-DA,
VIP values and Kruskal-Wallis test, we identified statistically important metabolites
that represent key changes occurring during embryogenesis (Fig. 3.1 & 3.2). The
additional layer of hierarchical clustering analysis further provides a useful
classification of metabolites with similar trends (Fig. 3.3). As OPLS-DA may
potentially overfit the data, a 7-fold internal cross-validation was performed to avoid
such an occurrence.
We observed the clustering of metabolites into distinct metabolite classes, which hint
towards regulatory control of specific metabolite types during embryogenesis. We
have demonstrated that clusters of amino acids, carbohydrates and lipids do exhibit
different trends. In comparison to previous zebrafish metabolomic studies (Hayashi et
al., 2009, 2011; Papan & Chen, 2009; Soanes et al., 2011), our work complements
them by providing a broader scope of identified metabolites as well as identifying
clustering trends for metabolite classes. Similar to their work, we have identified
metabolites such as glucose, creatine and phenylalanine, etc. Furthermore, we have
also expanded the scope using a combined GC-MS and LC-MS approach and
identified significant lipid changes, especially for phospholipids. Additionally, we
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also attempted to relate our metabolomic findings to possible enzyme mRNA
transcripts and proteomic data.
Several key metabolites have been identified to be crucial in distinguishing different
developmental time points. We observe that these metabolites serve fundamental
needs of a developing embryo – the provision of molecules for structural, energetic,
osmoprotective as well as antioxidative needs. Some metabolites were observed to
have a sustained increase at a late stage (48 hpf), which also indicate de novo
synthesis. This coincides with the formation and maturation of important organs such
as the liver, hence allowing de novo synthesis to occur. Free amino acids are
indispensible nutrients for embryogenesis and we observed a gradual rise of amino
acids that was sustained to the last time point of 48hpf. Based on previous studies, this
amino acid pool is supplied by the degradation of vitellogenin by a class of proteases
called cathepsins. Vitellogenin is a yolk protein that provides the embryo with
necessary amino acids, lipids and carbohydrates for the early phase of life (Denslow,
Chow, Kroll, & Green, 1999). The breakdown of vitellogenin is shown to be mediated
by cathepsins in teleost fishes (Brooks, Tyler, & Sumpter, 1997). Of particular
relevance here is cathepsin L that processes vitellogenin (Fig. 3.4D). It is believed
that yolk granules containing vitellogenin are processed at the boundary of yolk
syncytial layer by cathepsin L (Tingaud-Sequeira & Cerdà, 2007). Whole mount in
situ hybridization studies also show that cathepsin L-a is expressed in the YSL and
transcriptomic data further show that the L-a isoform remains at a relatively high level
during early embryogenesis, therefore  cathepsin L-a can be postulated to be the main
yolk processing enzyme (Tingaud-Sequeira & Cerdà, 2007).
88
Cathepsin D is another isoform that shows differential expression and has been
reported to be putatively involved in yolk processing for rainbow trouts (Kwon et al.,
2001). Spatially, Thisse et al. also showed that cathepsin D is expressed in the YSL
(Thisse & Thisse, 2004) and this strengthens the possible yolk processing role of
Cathepsin D. As for zgc:85774 (Cathepsin H), the surge of its expression may allow
for its preliminary association with yolk processing. However, its spatial expression is
currently unavailable and further in situ hybridization studies would be useful to
establish its expression in the YSL.
The sustenance of the embryo relies upon the generation of ATP. In this aspect, we
observe that phosphocreatine (PCr) and glucose could play a key role in providing
energy to the developing embryo. Utilization of PCr involves enzymatically
transferring a phosphate group from itself to ADP, creating creatine as a by-product
(Wallimann, Wyss, Brdiczka, Nicolay, & Eppenberger, 1992). The gradual
accumulation of creatine detected here may suggest that phosphocreatine could be a
key energy source during rapid early development. Another possibility of high
creatine levels may also be attributable to de novo synthesis of creatine during
embryogenesis (Braissant et al., 2005). From the changing trend of glucose, the high
levels of glucose at 48 hpf further hints at a larger dependency of this substrate during
that time point (Fig. 3.3). Hence an energy source transition from phosphocreatine to
glucose may be possible. Future studies involving flux studies may help elucidate this
clearer.
Betaine (also known as trimethylglycine) was upregulated as embryogenesis
progresses and the high level of betaine was observed at 48 hpf could indicate the
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onset of de novo synthesis. Physiologically, betaine is a methyl donor for important
metabolic activities such as methionine cycle (Craig, 2004) necessary for proper
development. The significance of increased betaine may lie in its role as a natural
osmoprotectant. It is known to protect mouse preimplant embryos against increased
osmolarity in vitro (Anas et al., 2008; Hammer & Baltz, 2002).  A study further
showed that betaine accumulated in cells when exposed to hypertonic solutions and
protects cells against apoptosis (Alfieri et al., 2002). However, given that dissipation
of excreted products would occur readily in aquatic system, we postulate that the role
of betaine as a methyl donor is more likely to be important.
Among the biological classes of molecules, nucleobases are important in DNA and
RNA synthesis. A key nucleobase that provides for nucleotide synthesis is
hypoxanthine. Though high in levels at the start of embryogenesis, hypoxanthine
starts to decline sharply towards around 12 hpf (Fig. 3.4E). Given the context of
hypoxanthine in embryogenesis, we postulate that hypoxanthine is converted/salvaged
into nucleotide precursors such as inosine monophosphate and guanine through the
enzyme hypoxanthine-guanine phosphoribosyltransferase (Hprt) (Alexiou & Leese,
1992; Voet & Voet, 2004a). Transcriptomic data reveals a spike in hprt1 mRNA prior
to the decline of hypoxanthine levels, supporting the view that synthesis of hprt1
enzyme salvages hypoxanthine into other precursors.
Rapid embryonic development is an energy exhaustive process where oxidative stress
is likely to be incurred through aerobic metabolism (Guérin, El Mouatassim, &
Ménézo, 2001). The susceptibility of embryos to reactive oxygen species (ROS)
affects proper development and hence the level of oxidative stress needs to be
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attenuated (Dennery, 2007). Oxidative stress is often mediated by glutathione (GSH)
that neutralizes free radicals and peroxides. GSH levels are upregulated for most
sampled time points except for 8 & 12 hpf (Fig. 3.4F). The accumulation of
pyroglutamic acid (5-oxoproline) may reflect an inability to further process γ-
glutamylcysteine into GSH, producing pyroglutamate as a by-product(G Wu, Fang,
Yang, Lupton, & Turner, 2004).  Glutathione synthesis consists of the condensation of
glutamate, cysteine and glycine via a two-step process. Glutamate-cysteine ligase
plays an important role in the rate-limiting step of synthesizing gamma-
glutamylcysteine (GGC), before it is converted to glutathione. We observed the
upregulation of the enzyme’s modifier subunit at 12 hpf (Fig. 3.4F), which controls
the enzyme’s catalytic efficiency and hence increase production of GGC which is a
precursor for glutathione. Although the mRNA level of modifier subunit decreased
past 12hpf, sufficient translation of this mRNA could have provided a sustained level
of modifier subunit protein to drive GSH biosynthesis. Despite being able to establish
the enzyme transcript-substrate relationships, the flux of the metabolite in a pathway
still remains difficult to ascertain, unless specific studies e.g. using C13-labeled
substrates, are performed.
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Carnitine and isocitrate are molecules intimately related to the mitochondrion.
Carnitine transports acyl chain of fatty acids into the mitochondrion where the acyl
chain is broken down via β-oxidation into acetyl CoA (Hoppel, 2003). Isocitrate is a
substrate of the Krebs cycle which occurs within the mitochondrion (Voet & Voet,
2004a). Both carnitine and isocitrate are downregulated as embryogenesis progressed,
possibly due to higher rates of utilization or conversion into other substrates as the
embryo divides and grows. The temporal protein expression of aconitase and
isocitrate dehydrogenase around 6-18 hpf (Table 3.3) may further explain reduced
isocitrate levels after 4 hpf. Interestingly, these enzymes were below detection limit
after 14-18hpf, which could suggest the importance of other energy-generating
mechanisms such as glycolysis, that have enzymes detectable beyond 18hpf.
A diverse range of lipids was detected and they were mainly phosphatidylcholines
(PCs), lysophosphatidylcholines (LPCs), cholesterol and alpha-tocopherol (Vitamin
Fig. 3.8 A summary of upregulated and downregulated metabolites detected through the
different stages of zebrafish embryogenesis. Downregulated metabolites are depicted with
dashed lines, whereas upregulated metabolites are referenced with solid lines.
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E). Cholesterol plays a unique role in developmental regulation, where it is covalently
bonded to C-terminus of the sonic hedgehog (Shh) protein. This protein modification
is essential for normal range signaling of Shh (Lewis et al., 2001) to regulate
development. Cholesterol is further involved in the process of steroidogenesis, where
it serves as a common precursor for other steroids (Hsu, Hsu, Hu, & Chung, 2006).
Vitamin E is present in high levels in most teleost eggs where it serves as an
antioxidant and improves survivability of embryos (Palace & Werner, 2006). PCs are
the predominant phospholipids in teleost eggs and our data supports this view
(Wiegand, 1996). Physiological energetic of another teleost fish embryo (Atlantic cod)
shows that lipids contribute some 30% of catabolism, within which PCs comprise 60%
of it(Finn, Henderson, & Fyhn, 1995). The downregulation of certain PC species may
hence be linked to catabolism. However, a detailed functional analysis of these lipids
still remains an enigma at the present moment. A graphical summary of metabolite
regulation throughout embryogenesis is given in Fig. 3.8.
The concept of using zebrafish metabolomics for toxicological study was
implemented in Section 2.5, where embryos treated with NDMA were profiled using
LC-MS and GC-MS. The results complement existing morphological approaches that
monitor death and abnormalities of embryos. The general trend of decreased amino
acids and lipids have allowed us to differentiate the biological states between control
and treated embryos. As this pilot study was initiated as a proof of concept, detailed
analysis of metabolites and their biological roles is beyond the scope of this chapter.
The data from both zebrafish studies suggests that metabolomics goes beyond the
physical indicators (e.g. morphology change) and allows for a deeper analysis of
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perturbed metabolic processes. Metabolic processes are likely to precede any physical
indication of effect/damage as they are highly dynamic and fundamental components
of a living system. Measuring metabolic changes could reveal subtle effects that occur
before physical indicators manifest. Therefore metabolomics can be a useful
extension of basic zebrafish toxicology work to facilitate deeper understanding.
3.5 Conclusion
Our study of metabolic changes during zebrafish embryogenesis has offered us a
glimpse of dynamic changes in metabolism across several different developmental
time points. Based on the regulation of metabolites observed here, we can further
extrapolate and understand their implications in molecular pathways and ultimately
how it contributes to overall growth.
Toxicological insult is likely perturb proper metabolism and may alter metabolite
levels critical for proper embryogenesis. On the premise that toxicological insult
could indeed alter metabolism, we applied metabolomics to embryos treated with
NDMA to test this hypothesis. We showed that despite the lack of overt
morphological changes and mortality rate, differential profiles and metabolites related
to dose were found.
In summary, zebrafish embryos are a promising testing model that can facilitate
toxicological investigations with untargeted metabolomics. The results have been
promising and we assert that future toxicological studies based on metabolomics may
open up new molecular leads.
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Supplementary Information
Supplementary Information 1. Data pre-processing and mining
Each chromatogram obtained from GC-MS and LC-MS analysis was
converted to .AIA and .xml respectively using MassHunter (Agilent). The data were
further pre-processed using MZmine 2.014 to generate discrete peak lists containing
m/z, retention time (RT) and ion abundance (peak intensity). Within MZmine 2.0, the
data from different samples were combined into a single matrix by aligning peaks
with the same m/z and RT for GC-MS and LC-MS data, respectively. The cut-offs for
minimum time span are 0.01 min (GC-MS with min. height 5000.0 and tolerance of
m/z 0.500) and 0.1 min (LC-MS with min. height 10000.0 and tolerance of m/z 0.500).
The area of each peak was normalized to that of internal standard (FMOC-glycine) in
each data column of the matrix (variables in rows; observations in columns). The data
was subsequently filtered by the presence of peaks in at least 80% of each sample
category15 using Microsoft Excel.
The pre-processed GC-MS and LC-MS data were exported to SIMCA-P 11.0
(Umetrics AB, Umeå, Sweden) for analysis and visualization using multivariate
statistical methods. Two multivariate analysis methods were used to find the optimal
separation of clusters, namely the principal component analysis (PCA) and orthogonal
projection to latent structure-discriminant analysis (OPLS-DA). For PCA & OPLS-
DA, all data were mean-centered and unit variance scaled. A 7-fold cross-validation
was applied to both PCA & OPLS-DA and the reliabilities of models were further
rigorously validated by permutation tests.
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The variable importance in the projection (VIP) values reflect the importance
of terms in the OPLS-DA model both with respect to Y, i.e. its correlation to all the
responses, and with respect to X (the projection). Thus, metabolites with VIP value
greater than one (>1) were selected for further testing and validation using Kruskal-
Wallis Test (p < 0.05). The selected compounds from GC-MS analysis were identified
by comparison of mass spectra and retention time with those of reference standards,
and those available in libraries (NIST 2005), While those from LC-MS detection were
searched in the Human Metabolome Database (HMDB, www.hmdb.ca) first using ion
mass and then were further identified by either MS/MS fragmentation pattern or
reference standards16.
Heatmaps of identified metabolites were generated using MultiExperiment
View Version 4.817 and further analyzed using agglomerative hierarchical cluster
analysis based on Pearson correlation distances with gene leaf optimization. The
Kruskal-Wallis Test was also performed within this software package.
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Chapter Four
An integrated LC- and GC-MS
approach for investigating non-
proteinuric chronic kidney disease
This work has been published in Diabetologia (2012)
DPK Ng, A Salim, Y Liu, L Zou, FG Xu, SM Huang, H Leong, CN Ong. A




Rationale: The presence of protein in urine (proteinuria) has been a key diagnostic
criterion of renal damage and chronic kidney disease (CKD). Among diabetic (Type
II) patients with CKD, a subgroup was found to lack this symptom despite suffering
from CKD. Therefore it is of clinical interest to investigate possible causes of this
phenomenon using their urine samples. Metabolomics has the potential to detect a
broad range of small molecules in urine and may discover molecules that could be
significantly elevated/decreased in this non-proteinuric subgroup
Hypothesis: Apart from the absence of proteinuria, the non-proteinuric diabetic
patients may exhibit a different urinary profile compared to proteinuric diabetic
patients. Metabolomic investigation of their urine samples may reveal new insights
and potential biomarkers
Objective and Methods: Urine samples from patients of the Singapore Diabetic
Cohort Study (SDCS) were selected based on proteinuria, diabetic and CKD status
(estimated glomerular filtration rate (eGFR)). Patients were identified as being non-
proteinuric using multiple urinalyses and categorized as cases (n=44, eGFR <60 ml
min-1 1.73 m-2 (low eGFR)) and controls (n=46, eGFR ≥ 60ml min -1 1.73m-2) as based
on Modification of Diet in Renal Disease formula. Patients were further matched for
gender, age and ethnicity to reduce confounding factors. Urine samples were analysed
using LC-MS and GC-MS and statistically analysed using multivariate and univariate
analysis.
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Measurements and Main Results: Based on OPLS-DA, the urine samples were
shown to have two discernable metabolic profiles and after testing for significance
and robustness, 30 biomarkers were found to predict well for the non-proteinuric
CKD patients. Of these biomarkers, 11 GC-MS metabolites were strongly associated
with low eGFR after correction for multiple hypotheses testing (smallest adjusted p
value=2.62×10−14, largest adjusted p value=3.84×10−2). In regression analysis,
octanol, oxalic acid, phosphoric acid, benzamide, creatinine, 3,5-dimethoxymandelic
amide and N-acetylglutamine were selected as the best subset for prediction and
allowed excellent classification of low eGFR (AUC=0.996). In LC-MS, 19
metabolites remained significant after multiple hypotheses testing had been taken into
account (smallest adjusted p value=2.04×10−4, largest adjusted p value=4.48×10−2),
and several metabolites showed stronger evidence of association relative to the
uraemic toxin, indoxyl sulphate (adjusted p value=3.03×10−2). The potential effect of
confounding on the association between metabolites was excluded.
Conclusions: Metabolomics allows for a global profiling of urinary small metabolites
and generates useful biomarkers that are indicative of disease. These biomarkers
would be useful complements to the existing paradigm of using estimated glomerular





Chronic kidney disease (CKD) is a public health problem affecting 5–10% of the
world population (Eknoyan et al., 2004). It is characterized as a loss of renal function
over a period of time, which can span over months or years. Typically, CKD is
diagnosed through screening tests of individuals for other co-existing conditions
(comorbidity) such as high blood pressure or diabetes (Retnakaran, Cull, Thorne,
Adler, & Holman, 2006). A key diagnostic criterion would be the presence of
abnormally high protein levels in urine, known as proteinuria. However, there exists a
group of patients who are concurrently diabetic and have CKD, but yet do not exhibit
proteinuria (MacIsaac et al., 2004). In medical screening, such patients would not be
accurately diagnosed and be considered as patients at risk of having CKD.
This points towards the limitations of current screening methods such as proteinuria
detection and hence motivates the search for more sensitive biomarkers for this
unique patient class. Metabolomics would potentially be able to detect a broad range
of metabolites in the urine samples and systematically deduce biomarkers that could
discriminate between non-CKD and CKD diabetic patients. From here on, we would
refer to CKD patients as patients suffering from both CKD and type II diabetes,
whereas controls refer to type II diabetic patients with no CKD.
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Table 1. Clinical characteristics of cases and controls
Variable Cases (n=44) Controls (n=46) p-value
Age (years) 67.93±8.96 60.80±9.39 0.0004
Male 19 (43.2) 13 (28.3) 0.1390
Age at diabetes diagnosis (years) 58.27±10.90 52.18±10.58 0.0129
Duration of diabetes (years) 9.46±9.60 8.50±7.72 0.8975
Current modality for diabetes treatmenta 0.2240
Diet and exercise only 13 (30.2) 9 (21.4)
Oral hypoglycaemic agent with/without diet and exercise 25 (58.1) 32 (76.2)
Oral hypoglycaemic agent + insulin 4 (9.3) 1 (2.3)
Insulin alone 1 (2.3) 0 (0.0)
HbA1c (%) 7.4±0.96 7.07±0.67 0.0701
HbA1c (mmol/mol) 57.37±7.34 53.77±10.50
Systolic blood pressure (mmHg) 136.48±14.98 133.33±11.74 0.2963
Diastolic blood pressure (mmHg) 74.82±8.82 76.17±6.86 0.4167
Mean arterial pressure (mmHg) 95.387±8.90 95.22±6.54 0.9857
Triacylglycerol (mmol/l) 1.64±0.81 1.40±0.50 0.0941
Cholesterol (mmol/l) 4.61±0.76 4.68±0.89 0.7459
LDL-cholesterol (mmol/l) 2.60±0.60 2.77±0.77 0.2560
HDL-cholesterol (mmol/l) 1.27±0.29 1.28±0.30 0.8860
Serum creatinine (μmol/l) 113.75±23.31 74.37±16.36 <0.0001
Waist hip ratio 0.90±0.06 0.87±0.06 0.0705
BMI (kg/m2) 24.92±3.69 24.86±3.68 0.9426
eGFR (ml min−1 1.73 m−2) 51.66±6.88 83.61±16.06 NA
Smoking 0.817
Yes 4 (9.01) 3 (6.5)
Never 33 (75.0) 37 (80.4)
Ex-smoker 7 (15.9) 6 (13.0)
ACR d (μg/μmol)
Mean ± SD 2.45±5.69b 2.45±3.64 0.999
Median (IQR) 1.06 (1.63) 1.31 (2.14) 0.168
a. Treatment information is missing for one case and four controls
b. Mean and subsequent SD were computed after removal of one outlier
c. NA, not applicable
d. ACR refers to Albumin/Creatinine Ratio
Continuous variables were presented as Mean +/- SD, while categorical variables were presented as n (%)
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4.2 Materials & Methods
4.2.1 Patients and urine samples
All patients for this study were from the Singapore Diabetes Cohort Study (SDCS).
Briefly, the recruitment process of SDCS was as follows. Since 2004, all patients
previously diagnosed as having type 2 diabetes and treated at primary care facilities of
the National Healthcare Group Polyclinics in Singapore were invited to join SDCS.
Patients with a history of mental illness were excluded. Of the patients approached, 91%
agreed to participate in the study and formed part of the cohort. Consenting patients
completed a questionnaire to elicit information on demographics, lifestyle factors and
medical family history and also had their physical measurements taken. Random (not
first morning) spot urine specimens were typically collected in the morning at the
outpatient polyclinic and used for laboratory analyses.
Medical records were reviewed to obtain information on their metabolic control and
the presence of co-morbidities and complications including any history of non-
diabetic kidney disease. Lipid measurements were performed on fasting blood
samples. The research protocol was approved by both the National University of
Singapore Institutional Review Board and the National Healthcare Group Domain-
Specific Review Board, and patients participating in this cohort gave informed
consent. A detailed description of patient characteristics can be found in Table 1.
4.2.2 Definitions of non-proteinuria and low eGFR
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Patients in this metabolomic study were identified as being nonproteinuric using
multiple spot urine samples. To thoroughly exclude the presence of proteinuria, urine
samples were required to test negative on Labstix (Bayer Corporation, Elkhart, IN,
USA) or Micral-Test (Boehringer Mannheim, Mannheim, Germany) or have an
albumin/creatinine ratio (ACR) <3.5 μg/μmol (Exocell, Philadelphia, PA, USA) on at
least two of the last three urinalyses.Most of the patients were therefore likely to be
normoalbuminuric, although it was possible for some to have microalbuminuria
especially if this was transient. eGFR was calculated using the simplified
Modification of Diet in Renal Disease (MDRD) equation, where eGFR (ml min−1
1.73 m−2)=186.3×(plasma creatinine in μmol/l×0.011)−1.154×(age in
years)−0.203×(0.742 for women)×(1.21 if subject is black). Cases (n=44) were
defined as patients with eGFR <60 ml min−1 1.73 m−2, and controls (n=46) had eGFR
values ≥60 ml min−1 1.73 m−2. As a history of cataract was strongly associated with
low eGFR in SDCS (data not shown), presence of this complication was used as an
exclusion criterion to eliminate potential confounding.
4.2.3 Metabolomic analysis using GC-MS
Urine samples (20 μL) were incubated with 20 μL (10 mg/mL) urease enzyme for 30
min at 37°C. Then urease and other proteins were precipitated with 180 μL ice-cold
methanol, which contained 10 μg/mL 9-fluorenylmethoxycarbonyl (FMOC)-glycine
as an internal standard. After separation by centrifugation (16 relative centrifugal
force [rcf]×10 min, 4°C), 100 μL supernatant fraction was dried under nitrogen and
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derivatised with 150 μL methoxamine (50 μg/mL in pyridine, 37°C×2 h) followed by
150 μL MSTFA (37°C×16 h). After centrifugation (4°C, 6 rcf×1 min), the supernatant
fraction was injected into GC-MS. The derivatised sample (1.0 μL) was introduced by
splitless injection with an Agilent 7683 Series autosampler into an Agilent 6890 GC
System (both from Agilent Technologies, Santa Clara, CA, USA) equipped with a
fused-silica capillary column HP-5MSI (30 m×0.25 mm i.d., 0.25 μm film thickness)
as reported previously (Xu, Zou, & Ong, 2010). The inlet temperature was set at
250°C. Helium was used as the carrier gas at a constant flow rate of 1.0 mL/min. The
column effluent was introduced into the ion source of an Agilent 5973 Mass Selective
Detector (Agilent Technologies). The transfer line temperature was set at 280°C and
the ion source temperature at 230°C. The mass spectrometer was operated in electron
impact mode (70 eV). Data acquisition was performed in full scan mode from m/z 50
to 550 with a scan time of 0.5 s. The compounds were identified by comparison of
mass spectra and retention time with those of reference standards, and those available
in libraries (NIST 0.5). A total of 106 peaks with specific retention times in GC-MS
analyses were detected in this study.
4.2.4 Metabolomic analysis using LC-MS
The urine samples were diluted 1:1 with methanol (containing 10 μg/mL FMOC-
glycine as an internal standard) before being vortex-mixed for 3 min. After separation
by centrifugation (16 rcf×10 min, 4°C), the supernatant fraction was injected for LC-
MS analysis. LC-MS analysis was performed on an Agilent 1200 HPLC system
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(Agilent Technologies, Waldbronn, ermany) equipped with a 6410 QQQ triple
quadrupole mass detector and managed by a MassHunter workstation. The column
used for the separation was an Agilent rapid resolution HT Zorbax SB-C18 (2.1×50
mm, 1.8 μm; Agilent Technologies, Santa Clara, CA, USA). The oven temperature
was set at 50°C. The gradient elution involved a mobile phase consisting of (A) 0.1%
formic acid in water and (B) 0.1% formic acid in methanol. The initial condition was
set at 5% of B. The following solvent gradient was applied: from 5% B to 100% B
within 20 min, then hold for 2 min. Flow rate was set at 0.2 mL/min, and 5 μL of
samples was injected. The electrospray ionisation mass spectra were acquired in
positive and negative ion mode. The ion spray voltage was set at 4,000 V. The heated
capillary temperature was maintained at 350°C. The drying gas and nebuliser nitrogen
gas flow rates were 10 L/min and 207×103 Pa, respectively. For full scan mode
analysis, spectra were stored from m/z 100 to 1,000. A total of 144 peaks with
specific retention times in LC-MS analyses were detected in this study. The
compounds were searched for using the Human Metabolome Database
(www.hmdb.ca) using ion mass and further identified by either MS/MS fragmentation
pattern or reference standards.
4.2.5 Metabolomic data preprocessing
Each chromatogram obtained from GC-MS and LC-MS analysis was processed for
baseline correction and peak area calculation manually. The data were combined into
a single matrix by aligning peaks with the same mass and retention time for GC-MS
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and LC-MS data, respectively. The area of each peak was normalised to that of the
internal standard in each dataset. There was no further normalisation of the
metabolites with respect to creatinine because the level of this metabolite was
different between cases and controls (Tables 2 and 3).
4.2.6 Statistical analysis
Statistical comparison of clinical characteristics between cases and controls was
performed using two-sample t tests in the case of quantitative traits. In the event
where the data distribution deviated from normal distribution, Mann–Whitney tests
were used. For qualitative traits, comparison between cases and controls was
performed using Fisher’s exact tests.
The pre-processed metabolomic data were exported into Soft Independent Modeling
of Class Analysis (SIMCA)-P (version 11.0; Umetrics AB, Umea, Sweden) for
orthogonal partial least-squares discriminant analysis (OPLS-DA). To compare
median signal intensities of the metabolites between cases and controls, the Mann–
Whitney test was applied to each metabolite separately. The resultant p values for all
metabolites were subsequently adjusted to account for multiple hypotheses testing.
The false discovery rate (FDR) method of Benjamini and Yekutieli (Yekutieli &
Benjamini, 2001) was used to perform the adjustment.
To determine how well these metabolites performed in separating cases from controls,
we used two approaches. In the first approach, principal component (PC) analysis was
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performed for metabolites with a statistically significant association in the univariate
analysis. The first and second PC scores were then used as predictors in the logistic
regression model, with case status as the outcome. To ensure that the PC estimates
were robust, any outlying observations that lay more than four standard deviations
from the mean were removed. The receiver operating characteristic (ROC) curve for
the logistic model was calculated, and the AUC was used to assess the quality of
prediction, with AUC closer to 1 indicating better performance.
The second approach involved selecting the best subset of metabolites that can be
used to predict case status. Least absolute shrinkage and selection operator (LASSO)
logistic regression (Tibshirani, 1997) was used, with the optimal LASSO estimate
determined using leave-one-out cross-validation. Briefly, LASSO logistic regression
is very similar to the ordinary logistic regression, except that LASSO places
restriction on the number of metabolites with non-zero regression coefficients. The
LASSO algorithm optimally selects this subset of metabolites with non-zero




Cases and controls were comparable in most clinical characteristics except that cases
were older at the time of recruitment and had higher serum creatinine values, as
would be expected as these variables were directly used to compute eGFR values in
the MDRD equation (Table 1). Cases were also older than controls at the time of
diabetes diagnosis, but this difference was borderline significant (unadjusted
p=0.0129). ACR values were similar between cases and controls (Table 1).
Fig. 4.1 OPLS-DA score plot obtained from GC-MS data based on 106 peaks. Black
circles, controls (n=46); white circles, cases (n=44). The x-axis t[1] and y-axis t[2] indicate the
predictive component and orthogonal component, respectively.
4.3.2 GC-MS analyses
OPLS-DA revealed that cases could be clearly segregated from controls on the basis
of the 106 peaks detected by GC-MS (Fig. 4.1). Univariate analyses of the metabolite
signal intensities revealed striking associations between 24 metabolites and low eGFR
(unadjusted p<0.05; Table 2). Of these 24 associations, 11 remained statistically
significant after correction to account for multiple hypotheses testing (adjusted
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p<0.05). In particular, the p values associated with six metabolites (oxalic acid,
octanol, N-acetylglutamine, 3,5-dimethoxymandelic amide, benzamide and
phosphoric acid) were very small, with the largest p value=7.28×10−5 (phosphoric
acid) and the smallest p value=2.62×10−14 (oxalic acid). Urinary creatinine was also
higher in cases than controls (p=6.46×10−8; Table 4.2).
PC analysis was next performed to determine the clustering of the 24 metabolites. The
first two PCs of GC metabolites explained 56.5% of correlations between these
metabolites. The first PC axis is a contrast between phosphoric acid (metabolite 4)
and 3,5-dimethoxymandelic amide (metabolite 13) on the one hand and the rest of the
metabolites (Fig. 4.2). The second axis was largely responsible for the separation of
cases and controls, and could be characterised by a group of metabolites that tended to
have higher signal intensities in controls (phosphoric acid [metabolite 4], 3,5-
dimethoxymandelic amide [metabolite 13], benzamide [metabolite 7], L-serine
[metabolite 6], D-glucuronic [metabolite 20], oxalic acid [metabolite 3], succinic acid
[metabolite 5] and uric acid [metabolite 22]) and metabolites that were of higher
signal intensity among cases, including creatinine (metabolite 10), N-acetylglutamine
(metabolite 23) and octanol (metabolite 2). On the basis of these first and second PCs,
the cases could be separated quite well from controls. With the diagonal line in Fig.
4.2 used as a simple rule for separating cases from controls, all controls were placed
below the line and all but five cases were located above it. In logistic regression
where the first and second PC scores were used to classify participants into cases and
controls, the ROC curve revealed very good discriminatory power (AUC=0.999). The
above classification was achieved by using all 24 metabolites. However, from the
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univariate analysis (Table 4.2), it is clear that only a subset of metabolites was
significantly associated after adjustment for multiple testing, and, furthermore,
metabolites tended to show clustering, i.e., their signal intensities tended to vary
together across the different samples, as was evident in the PC plots. We therefore
next determined whether the same level of classification could be achieved with a
smaller select group of metabolites. With the use of LASSO logistic regression, the
following metabolites were selected as the best subset for case prediction: octanol,
oxalic acid, phosphoric acid, benzamide, creatinine, 3,5-dimethoxymandelic amide
and N-acetylglutamine.
Fig 4.2 PC analysis was next performed to determine the clustering of the 24
metabolites. The first two PCs of GC metabolites explained 56.5% of correlations between
these metabolites. Cases and controls can be differentiated along PC2.
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Table 4.2 Univariate analysis of metabolite signal intensities measured by GC-MS
Metabolites Control Cases Unadjustedp-value
Adjusted p-
valueMedian SD Median SD
Oxalic acid 0.263 -0.457 0 0 4.71×10−17 2.62×10−14
Octanol 0.287 -0.204 0.899 -0.596 9.65×10−13 2.68×10−10
3,5-Dimethoxymandelic
amide 0.764 -0.464 0.292 -0.181 4.75×10−11 6.98×10−9
N-Acetylglutamine 0.246 -0.735 1.811 -2.325 5.02×10−11 6.98×10−9
Creatinine 2.639 -3.237 11.224 -5.723 6.97×10−10 6.46×10−8
Benzamide 0.102 -0.026 0.079 -0.02 7.63×10−8 5.80×10−6
Phosphoric acid 43.706 -18.812 29.391
-
12.001 1.18×10−6 7.28×10−5
2-Hydroxyadipic acid 0.034 -0.025 0.056 -0.039 1.75×10−5 8.86×10−4
Ribonic acid 0.353 -0.61 1.168 -1.163 1.80×10−4 7.71×10−3
Hydroxyphenylacetic acid 0.123 -0.216 0.261 -0.38 6.98×10−4 2.43×10−2
Sarcosine 0.144 -0.247 0.183 -0.069 1.18×10−3 3.84×10−2
Salicyluric acid 0.849 -2.176 2.12 -4.442 2.10×10−3 6.50×10−2
Uric acid 1.847 -1.598 1.25 -1.435 2.34×10−3 6.85×10−2
ß-Hydroxybutyric acid 0.035 -0.061 0.07 -0.068 5.22×10−3 1.45×10−1
cis-Aconitic acid 0.128 -0.258 0.233 -0.518 7.02×10−3 1.86×10−1
2-Ketogluconic acid 0.073 -0.203 0.164 -0.258 9.35×10−3 2.36×10−1
Dodecanoic acid (C12:0) 0.346 -0.086 0.397 -0.236 1.48×10−2 3.42×10−1
Threitol 0.34 -0.451 0.689 -0.751 1.55×10−2 3.44×10−1
3-Hydroxyhippuric acid 0.308 -0.707 0.565 -0.719 1.97×10−2 4.20×10−1
Succinic acid 0.18 -0.177 0.137 -0.092 2.10×10−2 4.32×10−1
D-Glucuronic acid 0.088 -0.481 0.124 -0.267 3.05×10−2 5.47×10−1
Xylitol 0.762 -1.817 1.758 -1.782 3.73×10−2 6.21×10−1
Pseudouridine 0.903 -2.307 1.944 -2.482 3.66×10−2 6.21×10−1
L-Serine 0.106 -0.439 0.184 -0.446 4.71×10−2 7.27×10−1
Using these seven metabolites to predict case status, a classification (AUC=0.995)
was achieved that was as good as that previously derived using all 24 metabolites (Fig.
3). This led to the conclusion that higher signal intensities of octanol, creatinine and
N-acetylglutamine and lower signal intensities of oxalic acid, phosphoric acid,
benzamide and 3,5-dimethoxymandelic amide were all independent predictors of low
eGFR. Among the clinical variables, only age at diabetes diagnosis, age at recruitment
and serum creatinine were statistically significant in univariate analyses (Table 4.1).
113
In LASSO regression, only serum creatinine was selected into the model when the
significant metabolites listed above were included. The AUC of the model with serum
creatinine added is 0.996, which is very similar to the model without serum creatinine
(AUC=0.995).
Fig. 4.3 Prediction using GC-MS metabolites. Using seven GC-MS metabolites to predict
case status, a classification (AUC=0.995) was achieved. This is as good as that previously
derived using all 24 metabolites.
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Fig. 4.4 OPLS-DA score plot obtained from LC-MS data on 144 peaks. Black circles,
controls (n=46); white circles, cases (n=44). The x-axis t[1] and y-axis t[2] indicate the
predictive component and orthogonal component respectively.
4.3.3 LC-MS analyses
OPLS-DA revealed clear segregation of cases from controls on the basis of 144 peaks
detected in LC-MS (Fig. 4.4). Univariate analyses revealed a total of 32 metabolites
that were significantly associated with low eGFR (unadjusted p<0.05). Of these, 19
remained significantly associated after multiple hypotheses testing had been taken
into account (adjusted p<0.05; Table 4.3). Of these, 17 were detected in positive ion
mode, while two were determined under the negative ion mode, including indoxyl
sulphate, a well-established uraemic toxin (Niwa, 2010). Relative to indoxyl sulphate
(adjusted p=3.03×10−2), several metabolites clearly showed stronger evidence of
statistical association with low eGFR, with p values that were at least a magnitude
smaller. These included 4-methoxyphenylacetic acid, N6-acetyl-L-lysine, chondroitin
sulphate, citric acid, phenylacetyl-L-glutamine, 2-deoxyuridine and deoxypyridinoline
(Table 4.3).
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PC analyses of the LC-MS metabolites using the first two PCs explained 53.5% of
correlations. The metabolites had higher signal intensities among cases compared
with controls, with three clusters of metabolites being evident (Fig. 4.5).
Fig. 4.5 PC analyses of the LC-MS metabolites using the first two PCs explained 53.5%
of correlations. The metabolites had higher signal intensities among cases compared with
controls, with three clusters of metabolites being evident.
Compared with the GC-MS results, the separation of cases from controls was less
optimal, with only moderate discriminatory power (AUC=0.777), as observed using
the ROC curve (data not shown). LASSO regression revealed a subset of seven
metabolites (N6-acetyl-L-lysine, caffeine, 4-methoxyphenylacetic acid, chondroitin
sulphate, hyocholic acid/cholic acid/ursocholic acid, phenyl sulphate and α-
hydroxyhippuric acid) that best predicted case status with an AUC of 0.870, an
improvement on that achieved using PC scores (Fig. 4.6).
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Fig. 4.6 Prediction using LC-MS metabolites. ROC curve of seven LC-MS metabolites
achieved better AUC values compared to using first two PCs of LC-MS metabolites.
The potential effect of confounding on the association between metabolites and low
eGFR by patient clinical variables was excluded. In univariate analyses, age at
diabetes diagnosis, age at examination and serum creatinine were statistically
significant at the 5% significance level (Table 4.1). However, only age at recruitment
and serum creatinine were selected by LASSO regression when the significant
metabolites listed above were included. The AUC for this model where age at
recruitment and serum creatinine were added to the model was 0.978, which
represents a significant improvement over the model with metabolites only
(AUC=0.870). Validation In an attempt to provide some kind of validation for the
above GC-MS and LC-MS results, 45 individuals (23 controls, 22 cases) were
randomly selected from the 90 participants and used to discover the important
metabolites. These metabolites were then validated by calculating the AUC based on
the 45 remaining unselected participants. This random selection was repeated ten
times, yielding a range of AUC values. For GC-MS metabolites, the AUC for the
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validation set was consistent and ranged from 0.934 to 1.000. For the LC-MS
metabolites, the range was less optimal, with AUC values of 0.477–1.000.





p-valueMedian SD Median SD
Positive ion mode
4-Methoxyphenyl-
acetic acid 0.022 -0.031 0.08 -0.076 5.11×10
−7 2.04×10−4
N6-Acetyl-L-lysine 0.16 -0.069 0.258 -0.249 2.16×10−6 3.82×10−4
Chondroitin sulphate 0.057 -0.099 0.162 -0.213 2.39×10−6 3.82×10−4
Citric acid 0.261 -0.241 0.441 -0.435 3.60×10−6 4.80×10−4
Phenylacetyl-L-
glutamine 0.827 -0.993 1.693 -2.117 4.91×10
−6 4.91×10−4
2-Deoxyuridine 0.792 -0.565 1.554 -1.378 6.18×10−6 5.49×10−4




0.091 -0.105 0.157 -0.162 3.28×10−4 1.09×10−2
N-Acetylspermine 0.056 -0.08 0.168 -0.185 3.92×10−4 1.21×10−2
Creatinine 1.105 -0.753 1.581 -1.26 5.19×10−4 1.47×10−2
Sphingosine 0.112 -0.187 0.252 -0.671 5.51×10−4 1.47×10−2
3,7-Dimethyluric acid 0.131 -0.252 0.408 -0.462 6.75×10−4 1.69×10−2





0.085 -0.092 0.288 -0.202 8.52×10−4 1.85×10−2
Hyocholic acid/ cholic
acid/ ursocholic acidc 0.371 -0.418 0.501 -0.952 8.09×10
−4 1.85×10−2
Phosphoribosyl-
formylglycine amidine 0.065 -0.124 0.128 -0.342 1.42×10
−3 2.87×10−2
IDP 0 -0.183 0.052 -0.161 2.52×10−3 4.48×10−2
Caffeine 0.139 -0.189 0.307 -0.275 3.74×10−3 5.86×10−2
α-Hippuric acid 2.186 -2.54 3.543 -4.859 6.06×10−3 9.14×10−2
Pregnanediol-3-
glucuronide 0 -0.067 0.045 -0.168 8.23×10
−3 1.15×10−1
Suberylglycine 0.18 -0.161 0.284 -0.347 8.92×10−3 1.23×10−1
Vinylacetylglycine 0.525 -0.467 0.715 -1.211 1.65×10−2 1.97×10−1




0 -0.123 0 -0.206 2.40×10−2 2.69×10−1
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0.345 -0.65 0.597 -0.685 1.44×10−3 2.87×10−2
Indoxyl sulphate 10.484 -17.112 18.12 -20.359 1.56×10−3 3.03×10−2
α-Hydroxyhippuric
acid 0.606 -2.977 1.688 -4.975 3.31×10
−3 5.50×10−2
Urothion 1.162 -2.281 1.594 -2.05 5.76×10−3 8.86×10−2
Salicyluric acid 0.297 -0.863 0.794 -1.221 6.27×10−3 9.29×10−2
3-Oxocholic acid 0.603 -0.822 0.89 -1.091 2.42×10−2 2.69×10−1
Phenyl sulphate 2.592 -4.019 3.142 -7.253 4.80×10−2 4.84×10−1
4.4 Discussion
Our study has succeeded in unveiling a wealth of information linking a number of
urinary metabolites with low eGFR. Moreover, these novel and statistically robust
associations were found in diabetic patients who were persistently non-proteinuric and
thus would conventionally have been regarded to be at low risk of chronic kidney
disease.
The candidate metabolites for low eGFR extended well beyond the few widely
acknowledged uraemic toxins. Indeed, while we did find significant associations with
urinary levels of uraemic toxins such as indoxyl sulphate, creatinine and the
methoxylated form of phenylacetic acid, at least 13 other metabolites exhibited much
stronger evidence of an association with low eGFR, with p values that were at least a
magnitude smaller when compared with indoxyl sulphate (Tables 2 and 3). These new
candidate biomarkers include oxalic acid, octanol, 3,5-dimethoxymandelic amide, N-
acetylglutamine, benzamide, phosphoric acid, 2-hydroxyadipic acid, N6-acetyl-
Llysine, chondroitin sulphate, citric acid, phenylacetyl-Lglutamine, 2-deoxyuridine
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and deoxypyridinoline. Our literature review suggested that only a few of the
metabolites, such as creatinine, oxalic acid and phosphoric acid, had been earlier
linked to renal disease in humans (Mydlík & Derzsiová, 2010; Wills, 1985). While
raised serum creatinine serves as an indicator of renal function, urinary creatinine is
primarily used in the context of a 24 h creatinine clearance test to measure GFR.
Regarding oxalic and phosphoric acids, high urinary levels of these metabolites
predisposed to the formation of kidney stones (Worcester & Coe, 2010), but the effect
of kidney stones on reducing renal function remained unclear (Gillen, Worcester, &
Coe, 2005). It was noteworthy that the urinary levels of these metabolites were
actually lower in the cases than controls in our study.
Fig. 4.7 Oxalic acid as a potential biomarker. Oxalic acid is detected in higher levels in
controls compared to cases, suggesting a strong potential of oxalic acid in differentiating
cases and controls.
In particular, oxalic acid was detected in 44 out of 46 control participants (95.6%) but
in none of the cases (Fig. 4.7). This striking observation may be consistent with the
systemic retention of this metabolite in the presence of low eGFR. In this connection,
it is interesting to note that increased plasma oxalic acid levels had been previously
linked with chronic kidney disease (Mydlík & Derzsiová, 2008).
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Chondroitin sulphate is a type of glycosaminoglycan that is covalently linked to
proteins, forming proteoglycans. It is reportedly absent in the normal glomerular
basement membrane, but its content increases soon after the onset of experimental
diabetes (Karasawa, Nishi, Suzuki, Imai, & Arakawa, 1997; McCarthy, Abrahamson,
Bynum, St John, & Couchman, 1994). Semi-quantitative analysis suggested a
reduction in total urinary glycosaminoglycan content in diabetic animal models
compared with nondiabetic controls with increasing diabetes duration and this
appeared to correlate with albuminuria (Cadaval, Kohlman, & Michelacci, 2000). In
normoalbuminuric type 1 diabetic patients, increased urinary excretion of
glycosaminoglycans, including chondroitin sulphate, was related to poorer glycaemic
control and longer diabetes duration, although the association between the excretion
of these metabolites and eGFR was not reported (De Muro et al., 2002, 2006).
An important highlight of our study is the previously unrecognised roles of the
remaining metabolites in the modulation of eGFR. Even so, there may be some
underlying biological plausibility. For example, cases with low eGFR had lower
levels of benzamide compared with controls. Benzamide has been shown to be an
endogenous inhibitor of poly(ADP-ribose) polymerase-1 (PARP-1) (Banasik, Komura,
Shimoyama, & Ueda, 1992; Martin, Lewington, Hammerman, & Padanilam, 2000), a
key enzyme that has been strongly implicated in causing diabetes-associated
endothelial dysfunction (Garcia Soriano F et al., 2001). Pharmacological inhibition of
PARP-1 ameliorated various features associated with nephropathy in both
experimental models of type 1 and type 2 diabetes, including albuminuria (Shevalye,
Stavniichuk, et al., 2010; Szabó, Biser, Benko, Böttinger, & Suszták, 2006). Urinary
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albumin and protein excretion were reduced in the streptozotocin-diabetic mouse
model with the endogenous Parp1 gene constitutively ablated by gene knockout
(Shevalye, Maksimchyk, Watcho, & Obrosova, 2010). While these previous animal
studies concentrated primarily on the effect of PARP-1 in ameliorating albuminuria,
our present finding on benzamide provides intriguing fresh evidence of a role for
PARP-1 in the modulation of eGFR in diabetic patients.
Despite the salient findings, certain limitations of our study should be acknowledged.
First, our study was based on a case–control study design, and therefore we could not
draw conclusions regarding causation as in a cohort. This case–control study design
was, however, appropriate in the current instance because the comprehensive
metabolomic profiling of a large cohort would have been prohibitive in terms of both
logistics and costs. The selected metabolites here identified may now serve as
prospective leads in future cohort studies. These same logistic and cost considerations
also placed a necessary limit on our sample size, consequently reducing the power of
our study. However, this decreased power did not appear to substantially affect our
study, as we successfully detected a number of associations that remained robust after
correction for multiple hypotheses testing. Third, GFR was estimated using a serum
creatinine-based equation rather than being directly measured. This can be expected to
have caused some degree of disease misclassification and, conceivably, made it
harder to identify potential metabolites that had weaker associations with low eGFR.
Another potential shortcoming was that our metabolomic study was confined to urine
and not the corresponding blood specimens from the patients. This was due to the
inherent technical difficulties in metabolomic analysis of this complex biofluid.
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Characterisation of the blood metabolome may have provided a more holistic context
within which our findings could be interpreted.
To balance this, attention should be drawn to several strengths of our study. First, the
metabolomic approach used was comprehensive by leveraging both GC-MS and LC-
MS platforms. Second, positive and statistically robust associations were uncovered.
In addition, the detection of associations with known uraemic toxins provided some
degree of validation of our study design including the characterisation of our patient
sample. Third, the chance of false positive findings was minimised by careful
adjustment for multiple hypotheses testing. Fourth, our study focused on low eGFR in
non-proteinuric patients. Aside from yielding new insight into the renal aspects of
these patients, a significant benefit of our study design was the minimisation of any
potential confounding due to the presence of proteinuria on the associations between
the metabolomic profiles and low eGFR. Finally, to our knowledge, this is the first
study of the metabolomics of eGFR in human type 2 diabetes. Previous reports have
attempted to study changes in the urinary metabolome associated with type 2 diabetes
per se, without any attention being paid to their possible association with the
accompanying renal traits. Critically, few of these studies were on human specimens
(X. Zhao et al., 2010), with the majority being performed on experimental models of
diabetes (Cai et al., 2009; Patterson et al., 2011; L.-C. Zhao et al., 2010).
4.5 Conclusion
In conclusion, our investigation of the metabolomics of low eGFR in non-proteinuric
type 2 diabetic patients has yielded substantial biological insight. In addition, we have
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identified several potential candidate biomarkers that may prove useful for detecting
and monitoring chronic kidney disease. Individually, these potential biomarkers,
especially the seven GC-MS metabolites, showed highly significant associations with
low eGFR and had good discriminatory power. When used collectively, the
metabolomic signatures appeared to be promising for disease classification.
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Chapter Five
MetaboNexus – an interactive platform
for integrated metabolomics analysis
This work has been published in Metabolomics (2014)
SM Huang, WZ Toh, PI Benke, CS Tan, CN Ong. MetaboNexus: an interactive
platform for integrated metabolomics analysis Metabolomics 2014 Dec 10(6):1084-93
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Project Abstract
Rationale: Data analysis in metabolomics is a non-trivial task and combines expertise
from a wide range of disciplines such as chemistry, computing, statistics and biology.
As such, multiple software programs and repositories are required to analyse and
support findings at every juncture of metabolomics data analysis. An issue with this
approach lies in its inefficiency and poor amenability for optimization.
Hypothesis: The aggregation of multiple data analytic algorithm and databases under
one software would improve efficiency and amenability for optimization.
Objective and Methods: We used the R programming language to create a software
called MetaboNexus that is capable of peak detection, normalization, multivariate and
univariate analysis and database searches for metabolite and biochemical pathway
identification. It is easy to install and has a user-friendly graphical user-interface (GUI)
for users to alter parameters in the process of optimizing analysis. The use of parallel
computing would further improve computation speed especially during peak detection.
Measurements and Main Results: Using a testing set of raw data collected from
urine UPLC-QTOF spectra, we demonstrated the streamlined design of MetaboNexus
with timing data to justify improved efficiency. The 16 raw data files (size=0.5 GB)
were processed using a 64-bit (quad core) 3.2GHz Windows 8 Desktop with 8GB
RAM. An overall time of approximately 15 min was required to generate a list of
candidates suitable for further tandem MS and database matching.
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Conclusions: Improvements in analytical speed have been achieved with
MetaboNexus and the integrated nature of analytical steps and simple GUI allows





In metabolomics, the process of analysing raw mass spectrometry data often requires
multiple steps and different software programs to integrate large files for metabolite
identification. These steps can be generalized as peak pre-processing, data
transformation, statistical analysis and metabolite identification (Tomita et al., 2012).
These processes are usually time consuming and non-trivial. In order to reduce the
complexity and time for this workflow, several platforms that streamline these steps
were developed. Prominent examples include MetaboAnalyst (Xia, Mandal,
Sinelnikov, Broadhurst, & Wishart, 2012), XCMS Online (Tautenhahn, Patti, et al.,
2012) and MeltDB (Kessler et al., 2013). However, uploading raw data files to these
platforms can be a time consuming process, which can take hours (e.g. 10 UPLC-
QToF mzData files can potentially range from 400-1000MB depending on acquisition
settings). In addition, there is a potential risk of revealing sensitive clinical
information, if the data were not masked. Ideally, these processes should be to be
carried out on a standalone computer instead. Developers of MetaboAnalyst are also
cognizant of these issues and have made their platform downloadable, albeit only for
the Linux operating system.
It is therefore not surprising to note that in most publications researchers are using a
variety of specialized desktop software to handle the data and perform different parts
of the metabolomics workflow. Examples would be instrument-specific software
(Agilent, Waters, AB SCIEX and Thermo) and statistical analysis software (SIMCA-
P and SPSS). A key problem with this approach lies in the inefficiency of extracting
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information from each step and recombining it with other analysis outputs. For
example, after performing the multivariate and univariate analysis on two specialized
software (SIMCA-P from Umetrics and SPSS from IBM), there is a need to combine
their respective results back for the identification of the significant peaks, followed by
putative identification using MassBank (Horai et al., 2010), METLIN (Tautenhahn,
Cho, et al., 2012) or Human Metabolome Database (HMDB) (Wishart et al., 2009). A
qualitative comparison of some prominent web platforms/software can be found in
Table 1.
The open source software language, R (R Development Core Team, 2005), can be
used to develop a comprehensive metabolomics data analysis platform by using a
single program. Peak pre-processing and in-depth statistical analysis can be
performed with customized R scripting. However, its command-line interface is a
stark departure from the conventional clickable graphical user interface (GUI), which
is a genuine barrier for metabolomics researchers with little or no programming
background.
To address these limitations, we have developed MetaboNexus, an interactive
metabolomics data analysis platform that works on standalone computers without the
need for any web server connections. The key features of this platform are (1) easy-
to-use GUI, (2) comprehensive analytical toolbox, (3) automated generation of plots,
(4) comprehensive search engine that matches m/z values of significant peaks to three
major databases, and (5) tandem MS spectra and biochemical pathway information for
the metabolites. The interactivity of MetaboNexus allows the refinement of data
analysis parameters throughout the analysis workflow, leading to better data insights.
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Another advantage in having a workflow that performs all data analytical steps in one
platform is that it facilitates the reproducibility of findings. MetaboNexus was
designed mainly for the LC-MS experimental workflow, especially for pre-processing
and metabolite identification. However, it is still possible for MetaboNexus to
statistically analyze pre-processed data originating from GC-MS or NMR.  For users
interested in useful tools for GC-MS workflow, Tagfinder (Luedemann, Strassburg,




The main aim for developing MetaboNexus is to have a comprehensive and integrated
platform made available to a standalone computer. It is designed to create a seamless
workflow that transfers pre-processed peak data from raw files to a statistical
workflow that screens for significant peaks, and subsequently matching them to
databases for identification (Fig. 5.1). More specifically, the pre-processed peak data
will undergo multivariate analysis to derive a variable importance measure (e.g. VIP
values), and then undergo univariate analysis to obtain p-values and ROC area under
curve (AUC) values (Baker, 2003). The information from the multi- and univariate
analyses provides a shortlist of peaks deemed relevant towards the separation of two
or more sample classes. The shortlisted peaks can be easily identified using our
metabolite search function that matches m/z values to MassBank, METLIN and
HMDB. Additional tandem MS spectra and biochemical pathway information related
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to the identity of the metabolites can also be searched within the platform.  To achieve
faster processing, we have also designed MetaboNexus to run on multiple cores and
perform parallel processing.
Fig. 5.1 Design of MetaboNexus. As a desktop application, MetaboNexus performs all tasks
locally, without the need for large file uploads or job queues. Raw data is first pre-processed
and progressively analysed by multi- and univariate analyses. Variable importance measures
and p-values calculated from these two steps will serve as a means to shortlist candidates for
further metabolite identification. The metabolite identification function matches m/z values to
three databases for available identities, tandem MS spectra and biochemical pathway
information.
MetaboNexus is currently available for the Windows operating system, from version
XP or onwards. The entire platform takes up about 300MB, and works preferably
with the Google Chrome or the Mozilla Firefox browsers. For Chrome, we have
tested our platform on versions 32.0.1700.107 and onwards, while for Firefox, the
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same is for versions 25.0.1 and onwards. In general, 64-bit processors are expected to
give better data analysis performance than 32-bit processors, with a minimum of 4GB
of RAM and processing speed of 2.90 GHz installed. Installation instructions can be
found in a user tutorial that comes with the platform, which is available at the URL
indicated in the abstract. The platform comes in two modules: the pre-processing
module (Fig. 5.2) and the data analysis module (Fig. 5.3). Both come with a GUI,
which were actualized by scripts interpreted by the shiny package. Computations and
data-querying are performed by our customized scripts and packages contributed by
the R community (i.e. plsdepot, rgl, randomForest, xml, gplots, xcms, snow,
preprocessCore & caret).
Table 5.1 Qualitative assessment of MetaboNexus compared to other existing prominent
metabolomics platforms/tools
Feature MetaboNexus MetaboAnalyst XCMSOnline MeltDB SIMCA-P
Raw data pre-
processing
   
Normalization   
PCA     
PLS-DA    
Random Forest   
ROC test  
Standard univariate
tests
   
Search in ≥ 2
databases
 
Usable offline   (on LINUX) 
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Fig. 5.2 Screen grab of the MetaboNexus pre-processing module. This module offers a
user-friendly interface for XCMS processing that was previously usable only through R
command lines. Here users will find recommended presets for various instruments (e.g.
UPLC-QToF) as well as manual settings for optimal peak detection. Peak tables that are
generated can be quickly normalized using the ‘internal standard’ or ‘quantile normalization’
option available.
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Fig. 5.3 Screen grab of the MetaboNexus data analysis module. The first tab of
MetaboNexus shows the desired format of the data, with the variables (peaks) as the columns
and the observations (samples) as the rows. The Y column indicates the grouping/annotation
of your samples according to sample class. For supervised analysis, enter the column name
containing the Y variable on the sidebar panel. After getting the correct format and annotation,
the user can then move through the tabs in the data analysis module and perform data
analysis.
5.2.2 Method of use and file input
In order to create a user-friendly platform, we used the R programming language to
create GUI frontends that communicates with the analytical backend. At the frontend,
the GUI is displayed through a web browser such as Google Chrome or Mozilla
Firefox where data can be loaded in and progressively analysed by clicking on the
tabs. Each tab contains a specific method, such as multivariate or univariate analysis.
By clicking on the tabs, a particular method is triggered to generate plots and/or tables
of the results. It is also possible to skip the individual analysis steps and go right to the
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last tab to rapidly generate an overall list of data containing peak m/z values, retention
time, variable importance (e.g. VIP), p-values and also ROC AUC values.
5.2.2.1 Input 1: Pre-processing with MetaboNexus
The first step in metabolomics is the pre-processing of raw data using software, such
as XCMS (Tautenhahn et al., 2008) or MZmine (Pluskal et al., 2010), to generate a
peak list of molecular features. Hence prior to starting MetaboNexus, users can first
launch the pre-processing module by executing the batch file to pre-process their raw
data and channel it directly into MetaboNexus. This module provides a dashboard of
controls to intricately handle pre-processing based on the XCMS package in R.
Acceptable file formats for pre-processing are NetCDF (AIA/ANDI format), mzXML,
and mzData files. Presets for different instrument types have been written (e.g.
HPLC-QToF, UPLC-QToF; see Table 5.2), but the settings can also be manually
adjusted for raw MS data obtained by other types of instruments (Patti, Tautenhahn,
& Siuzdak, 2012). Detected peaks can be further filtered by a specified percentage of
samples at which peaks need to be present in each sample class. For example, if a
peak is not present in at least 80% of any sample class, then the peak is discarded.
Upon clicking “Start pre-processing” on the main tab, users can monitor the progress
by looking at the command prompt window and click the next tab for further steps. At
the last tab (Peak Table), a list of peaks will be displayed and stored in a temporary
folder for access by the data analysis module of MetaboNexus.
The typical XCMS output is a peak table that is not normalized. To address this gap,
we have created a function to allow normalization by internal standard or quantile
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normalization options. After normalization, users may also directly save the table for
their own customized analysis via the “Download” button.
5.2.2.1 Input 2: Pre-processing with other softwares (e.g. MZmine)
The second input method would be to use peak area or intensity tables originating
from other software when formatted according to some specifications. The file should
ideally be in .txt, .csv, or .tsv formats where it consists of peak area labelled with
“Peak ID”, “mz”, “RT” and sample names as columns, and the peaks as rows. An
example is attached in the Supplementary Information. Users can insert data into
MetaboNexus by clicking on “Choose File” (in Chrome browser) or “Browse…” (in
FireFox browser).
Table 5.2 Presets for pre-processing in MetaboNexus based on instrument type (modified













centWave 30 10 to
60
c(3,1000) Obiwarp 5 0.025 50%
HPLC/Q-TOF
(high res)
centWave 15 10 to
60
c(3,1000) Obiwarp 5 0.015 50%
HPLC/
Orbitrap
centWave 2.5 10 to
60
c(3,5000) Obiwarp 5 0.015 50%
UPLC/
Q-TOF
centWave 30 5 to 20 c(3,1000) Obiwarp 2 0.025 50%
UPLC/Q-TOF
(high res)
centWave 15 5 to 20 c(3,1000) Obiwarp 2 0.015 50%
UPLC/
Orbitrap
centWave 2.5 5 to 20 c(3,5000) Obiwarp 2 0.015 50%
*Minimum fraction refers to the minimum percentage/fraction of samples at which peaks need
to be present at least one sample class. For example, if a peak is not present in at least 50%
of any sample class, then the peak is discarded.
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5.2.3 Starting MetaboNexus
To run the data analysis module of MetaboNexus, run the batch file (*.bat) and
thereafter another browser window or tab will appear. If the pre-processing module
was previously used, the processed data can be quickly retrieved by checking the
relevant checkbox located in the left panel. We have also created and ensured that this
platform can recognize pre-processed data originating from other software (e.g.
MZmine), as long as it contains a table of m/z, retention time and peak area values
(see dummy data).  Non-XCMS peak table can hence be loaded into the browser
using the “Choose File” or “Browse…” button. Instructions are provided on the
browser illustrating the required format of data, with the availability of a sample
dataset provided as an example. It is advisable for users to run MetaboNexus on 64-
bit systems so that more memory can be allocated for computationally-intensive tasks,
but the platform works efficiently on 32-bit systems as well.
Pre-processed peak data are first analysed via multivariate analysis, where we have
included principal components analysis (PCA), partial least square-discriminant
analysis (PLS-DA) or Random Forest (RF) to analyse data in an unsupervised or
supervised manner.
5.2.3.1 Data transformation & annotation
Prior to statistical analysis, it is vital that the appropriate data transformation is
applied to the peak data. Here, we have made available the options for log10, log2, loge
transformation for users. If external peak data from other software are used, there may
be a need to transpose the data within MetaboNexus before commencing any analysis.
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Entries in the dataset that are either missing or zero are arbitrarily replaced with a
value that is equal to half the minimum non-zero value in the dataset. By setting a
higher minimum fraction in the pre-processing stage (e.g. 80%), the number and
effect of missing values would be reduced.
Next, the sample classes needs to be annotated in the data. This can be done through
the “Annotation” tab, where classes can be specified by a Y variable or manual
annotation. For data processed using our pre-processing module, the sample class
information would be automatically imported into MetaboNexus.
5.2.3.2 Principal Component Analysis (PCA)
For unsupervised analysis, PCA reduces the high dimensionality of the data into
interpretable two-dimensional or three-dimensional plots. Each principal component
(PC) explains a certain percentage of data variation and the first two PCs are used to
plot the scores of the sample observations. In order to assess the variation is explained
by each PC, a barchart is provided in the “Scree plot” tab. MetaboNexus uses the
nonlinear iterative partial least squares (NIPALS) (Wold et al 1987) algorithm for
PCA.
5.2.3.3 Partial Least Squares-Discriminant Analysis (PLS-DA)
In supervised analysis, the peak data (X) is mathematically related to a Y variable that
contains sample class information (e.g. as “0” or “1”). From the PLS-DA analysis
(Wold et al 2001), the goodness-of-fit to peak data and Y is calculated as R²X and
R²Y respectively. To assess the predictive ability of the generated PLS-DA model, a
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10-fold cross-validation is performed to generate a cross-validated R²Y, namely the
Q² value, which describes how well the model predicts Y. Cumulatively, when all the
components are considered, users can refer to the R²X (cum), R²Y (cum) and Q² (cum)
to evaluate the model alongside with the score plot. Important variables can be
inferred from the variable importance in the projection (VIP) values available in the
“PLS-DA VIP” tab. Diagnostic plots that cover predicted Y, goodness-of-fit and
residual plots are also available under the “Model Diagnostics” tab. A sample output
of PCA & PLS-DA can be found in Fig 5.4.
Fig. 5.4 Comparison of MetaboNexus & SIMCA-P 13. Using dummy data, we compared
the PCA & PLS-DA results from both MetaboNexus & SIMCA-P 13 to illustrate the plot output
& reliability of results.
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5.2.3.4 Random Forest (RF)
RF is a relatively new and useful classifier that is robust against overfitting and
suitable for multiple classes (Breiman 2002; Liaw and Wiener 2002). It is different
from the regression-based PLS-DA in algorithm and relies on constructing multiple
classification trees. Briefly, a process known as bootstrap aggregating (or bagging), is
used to randomly select training samples from the original training data. The testing
data is then used for classification, to assess the accuracy of the RF model. The
classification is performed using a specified number of variables and this number is
typically calculated using from the square root of the peak features/variables used
(i.e.√p). The data is repeatedly sampled to form 500 classification trees (default
settings) and the best classifying variables are “voted” from the 500 trees.
To evaluate the resultant model, users can look at the out-of-bag (OOB) error,
confusion matrix and the proximity matrix plot. The OOB error is an estimate of how
good the model performs, where a lower value indicates a better performing model. In
the confusion matrix, misclassified samples are shown in a table and each class is
given a classification error rate. Proximities between data observations are also
calculated within the RF and are displayed as a plot.
Important variables are described by the “Mean decrease in accuracy” and the “Mean
decrease in Gini”. Both describe the influence of the variable when removed from the
model in terms of decrease in prediction accuracy and classification homogeneity.
5.2.3.5 Merging Variable Importance with Univariate Analysis
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After obtaining variable importance measures from PLS-DA and RF, the next step
would be to calculate the p-values of the pre-processed peaks. Under the “Univariate
Analysis” tab, users can choose between parametric (ANOVA, t-test) and non-
parametric tests (Kruskal-Wallis, Mann-Whitney U). In the case where a log
transformation has been applied to the data (using our transformation function),
parametric tests can be applied to calculate the statistical significance of each
individual peaks, otherwise a non-parametric test should be considered.
When the “Univariate Analysis” tab is clicked, the p-values are automatically
calculated. A list of peaks would be shortlisted by a pre-specified cut-off value, e.g. p-
value ≤ 0.05, and the boxplots and/or ROC associated with these peaks would be
displayed. Users can further shortlist the peak by imposing PLS VIP values or RF
variable importance onto the previous cut-off, or apply a false discovery rate (FDR)
correction instead. Finally, the result table that contains all the calculated values will
be displayed for downstream analysis and identification, and can be downloaded for
future reference.
5.2.3.6 Metabolite Search & Pathway Information
MetaboNexus integrates existing databases into its statistical workflow where users
can use the statistical information gained from the previous steps to choose peaks for
identification. To begin, users can select the peak of interest from a drop-down list
and choose the appropriate adduct (e.g. [M+H]+ or [M+Na]+). The adduct information
is then used to calculate the mass of the non-charged molecule for database search. A
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list of putative identifications from HMDB will be automatically displayed, followed
by a weblink that searches METLIN based on the peak information.
For peaks matched based on HMDB, the tandem MS/MS spectra can be retrieved in
MetaboNexus by copying the HMDB ID of the metabolite (e.g. HMDB00020) into
the second box. As the database is constantly growing, not all spectra can be expected
to be available. In addition, HMDB also references MS spectra from the MassBank
database, which can be retrieved by clicking on the “MassBank” button.
Biochemical pathways are vital towards understanding the role of any metabolite.
Alongside the aforementioned tandem MS/MS spectral information, weblinks are also
generated to direct users to KEGG (Kyoto Encyclopedia of Genes and Genomes)
(Kanehisa et al 2012) or SMPDB (Small Molecule Pathway Database) (Frolkis et al
2010) to explore pathway connections to other enzymes and metabolites.
5.2.3.7 Heatmap
Heatmaps are useful visualization tools to provide a quick overview of how peaks are
regulated in the experimental samples. We have provided controls for hierarchical
clustering in the dendrograms, re-ordering of heatmap elements, colour gradients and
also a function to display only statistically significant peaks based on p-value and
variable importance cut-offs (Fig. 5.5).
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Fig. 5.5 Screen grab of the MetaboNexus platform. Metabolomics data from 16 morning
urine samples of healthy volunteers were pre-processed on the MetaboNexus pre-processing
module, then accessed and analysed in the data analysis module. Following the numbered
tabs on the platform, the user can progressively analyse the data using a variety of multi- and
univariate analysis, including PCA and univariate statistical tests. Visualization of the data can
be obtained in the form of a heatmap, with or without hierarchical clustering.
5.3 Results
5.3.1 Evaluating performance of MetaboNexus
We evaluated MetaboNexus using mzData files of urine samples acquired by a
UPLC-QTOF instrument to measure the speed of data processing and also the
convenience of our platform. All pre-processing and analysis were done on a 64-bit
3.2GHz quad core computer running on Windows 8 operating system, with 8GB
RAM (actual usable RAM: 6GB).
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First, 16 morning urine samples were acquired from healthy volunteers, with written
consent. The samples were then methanol-precipitated for protein removal and
centrifuged at 16.1×g to remove proteins prior to injection. The LC-MS spectra were
acquired using an Agilent 1290 UPLC system (HT Zorbax SB-C18) coupled to an
Agilent 6520 Q-TOF. A total of ~3,000 peaks were detected using the pre-processing
module with 80% filtering and was used for statistical analysis. Pre-processing and
normalization of all peaks took about 10 minutes using parallel computing on 4
processing cores. Without parallel computing, the latter process may take longer than
15 minutes. Due to the large number of peaks, it took slightly less than 1 minute to
log transform, remove redundant variables and display the list of peaks. PCA and
PLS-DA took 5-10 seconds each to perform, while RF only required less than 5
seconds. During the univariate analysis step, t-tests and ROC were simultaneously
performed and this took less than 1 minute. Generally, downstream analysis of the
pre-processed data took less than 5 minutes (Fig. 5.6).
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Fig. 5.6 The speed of the MetaboNexus platform. 16 raw mzData files containing the
spectra of male and female urine samples were processed using a 64-bit (quad core) 3.2GHz
Windows 8 Desktop with 8GB RAM. An overall time of approximately 15 min was required to
generate a list of candidates suitable for further tandem MS and database matching. Essential
diagrams such as score plots, boxplots and heatmaps were automatically generated during
the analysis. The plots could also be customized to better communicate one’s findings.
5.3.2 User experience
MetaboNexus was able to perform at a similar level compared with other web servers,
with its speed dependent on the specifications of computer on which pre-processing
and analysis are conducted. Users running the pre-processing module may encounter
insufficient memory due to the limitations of 32-bit systems. Thus, it is recommended
that users run MetaboNexus on a 64-bit computer, where more memory can be
allocated to the R program. It is noteworthy that despite using a 64-bit system with
parallel computing power, the processing of large experiments (containing 500-1000
runs) may encounter a processing speed barrier due to file design standards and
dependent libraries. The use of solid state drives (SSDs) may further improve the
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processing speed relative to conventional hard disk drives (HDDs) (Chen, Koufaty, &
Zhang, 2009).
Feedbacks from users were of the opinion that MetaboNexus expediently integrated
raw data into a comprehensive statistical workflow. The workflow was also rapid in
generating a list of significant peaks that users could quickly use for further studies
(e.g.  targeted tandem MS analyses). This not only saved time but also allowed
researchers to focus on downstream metabolite identification work. Previously, the
original XCMS package in R did not provide the facility to normalize peak area. Here
in MetaboNexus, we added normalization functions in our pre-processing module to
correct for systematic errors due to instrument drift.
During the analysis of data, MetaboNexus provided a responsive display of plots
(particularly boxplots and ROC), as well as fast metabolite search. The better
responsiveness of the program was primarily because there were no additional time
spent uploading or querying web servers and then downloading the results. The
comprehensiveness of the metabolite search was also of great value to the users. We
provided an extensive list of molecular adducts in both positive and negative modes
for users to rapidly query MassBank, METLIN and HMDB. The immediate visibility
of potential metabolite candidates with tandem MS spectral information across these
three databases gave users more biochemical information to better determine
compound identity.
Heatmaps can be generated with or without hierarchical clustering analysis (HCA)
and HCA tends to reorder sample observations into similar clusters. In some cases,
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the initial order of observations is important as they were pre-arranged in some
meaningful order. One example could be data pre-arranged in time series or disease
progression. By giving users the option of not reordering samples, the heatmap now
can preserves the desired order.
The convenience of downloading the overall data from the whole analysis also gave
users the opportunity to explore their results beyond the scope of MetaboNexus. In
addition, MetaboNexus generates a log file for every session, which documents all the
control settings used in the analysis of data. This log file can be downloaded into a .txt
file and shared among collaborators for better reproducibility and communication.
A difference between MetaboNexus and other webservers lies in the way the
metabolites are identified. For webservers, a list of potential matches is displayed for
each peak whereas MetaboNexus requires manual selection of peaks and adducts. The
advantage of our manual approach is that users can customize their search by
selecting possible adducts (related to the specific analytical method used for the
chemical analysis) and exercise their own judgment on how best to interpret the
results. However, the lack of automated peak matching may be slower and not
scalable for large number of peaks, hence this could indeed prove to be a
disadvantage, even though it allows users to assess results in curated manner.
5.4 Conclusion
We have developed MetaboNexus, an interactive metabolomics platform that is
capable of performing peak data pre-processing and downstream statistical data
analysis. Our motivations stem from efficiency, convenience, and security aspects of
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metabolomics data and the data analysis process. MetaboNexus serves as a
comprehensive platform that integrates various essential components of metabolomics
research, and is functional without the need of any data uploading to the web. The
intuitive design of the GUIs allows users to easily harness the power of the R
programming language and modern statistical techniques. Owing to the modular
structure of the platform and how the GUIs were developed, it is possible to further
expand MetaboNexus to include other forms of analysis, such as having more
multivariate analysis models (e.g. support-vector networks (Cortes and Vapnik 1995).
Other improvements may be in the form of more normalization options and utilization
of retention indices for enhanced metabolite identification. The entire platform, R
scripts, and other required files and documentations, including a user tutorial, are




Conclusions, Limitations and Outlook
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6.1 Conclusions
In this thesis, we assessed the applicability of metabolomics to biomedical and
environmental research. The specimens investigated spans from in vitro, in vivo to
human samples. In view of such diversity, we adopted different strategies to
overcome inherent sample complexity and variability. Based on the results in this
thesis, metabolomics has demonstrated its capability to discover insights related
exposure effects to toxicants/stressors (nanosilica & NDMA), disease etiology and
biomarker discovery (CKD).
In our in vitro model (MRC-5 cell line), we showed that dose-dependent metabolic
changes were profoundly altered while the morphology of cells remained relatively
unchanged. The changes were specifically related to amino acid, lipid metabolism as
well as increased oxidative stress. For the in vivo model (zebrafish embryo), we
showed that metabolic profiles changes during different junctures of embryonic
development. When embryos were exposed to NDMA, although the morphology and
mortality of embryos were not significantly affected, we showed that dose-dependent
metabolic changes occurred within the embryos. At the clinical level, new biomarkers
were discovered for the improved detection of CKD in patients lacking classical
symptoms of proteinuria. The information gleaned from this study also supported
work related to the disease etiology. These studies collectively show that
metabolomics can ‘scratch beneath the surface’ to inform researchers about
previously unknown biological insights and spur new research hypotheses.
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The overall findings in this thesis demonstrate that metabolomics can complement
and add value to existing methodologies in biomedical and environmental research.
Existing methods such as morphological observations and assays are typically specific
and thus only cover a narrow scope of effects. While they are necessary to assess
known and potentially crucial factors, a tool that measures a broader range of changes
can complement them further. Global profiling with metabolomics can provide more
extensive information about disease/stressor effects, especially when existing methods
do not show overt changes. Based on the studies investigating CKD, nanosilica and
NDMA exposure, metabolomics has complemented existing methods with new ways
to understand mechanisms of the respective disease and stressors.
As metabolomics improves through the use of higher resolution instruments, so does
the scale of data processing. In anticipation of the heavy data-processing, we
developed MetaboNexus as a software to streamline peak processing, statistical
analysis and metabolite identification as a coherent pipeline. Any upstream
modification of parameters (e.g. peak processing) can be reflected automatically
downstream (e.g. PCA score plots). This allows researchers to understand the impact
of their choices during optimization of parameters and also expedite the shortlisting of
potential features for tandem MS-MS. We have also provided parallel processing
algorithms to spread the processing load over multiple cores to improve speed.
In conclusion, metabolomics is global profiling tool that can be complementary to
existing methodologies in biomedical and environmental research. Given a good
experimental design that controls for biological variability and sample stability, as
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well as an efficient analytical process, metabolomics is well-poised to discover novel
insights and generate new hypotheses to advance research.
6.2 Limitations and Outlook
Although metabolomics has been shown to be promising, we noted several limitations
that could be improved in order to realize its full potential. They are namely
metabolite identification, biological interpretation and scalability of large experiments.
6.3 Metabolite identification
Metabolite identification is undoubtedly a crucial part of metabolomics that brings
identity to the numbers. One can only better understand the biological state of the
samples if the metabolites are known. However, not all peaks detected using mass
spectrometry can be identified despite having m/z and retention time information and
limitations exist for different instruments.
Identification is dependent on the completeness and data resolution of metabolite
databases. Multiple databases currently exist but to provide spectral information for
the entire metabolome is a huge undertaking and challenge. The number of LC-MS &
GC-MS reference spectra in Human Metabolite Database (HMDB) version 2.0 were
799 and 279 respectively. This grew to 1249 and 1220 respectively in version 3.0
(Wishart et al., 2013). In view of this coverage issue, the combined searching of
multiple databases such as METLIN and MassBank could help increase the number of
verifiable metabolites.
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Another improvement towards metabolite identification would be the use of retention
indices. In this aspect, LC-MS has less reproducible retention time/indices than GC-
MS and hence this information may not be as reliably used as GC-MS. It has been
proposed that the use of calibration standards could provide useful references when
comparing retention times of different experiments (Scalbert et al., 2009). When both
experimental and reference standard data have these calibration standards in place, it
becomes easier to compare spectra and to judge if m/z and retention time are indeed
similar.  These standards could consist of 5-7 compounds with different polarity that
would act as ‘positional markers’ during chromatographic separation. This method,
together with m/z information, may improve metabolite identification in LC-MS.
Informative guides on metabolite identification have been provided by MSI (Sumner
et al., 2007) and Salek et al. (Salek, Steinbeck, Viant, Goodacre, & Dunn, 2013)
6.4 Biological Interpretation
Biological interpretation is the next crucial step in metabolomics to draw insights and
conclusions about a disease/stressor. The task of understanding each metabolite is
confounded by the fact that metabolites can be involved in multiple pathways and that
the type of sample would change the interpretation accordingly (e.g. plasma vs urine).
In order to elucidate how metabolites are involved in different pathways, the use of
isotopes may pave the way towards establishing the pathway of metabolites. For
example, a study by Lane et al. (2011) showed that in cancer cells, 13C-glucose were
converted directly into 13C-lactate. The group went further to identify metabolites
carrying 13C atoms to trace the metabolic pathways undertaken by 13C-glucose. Such
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studies can provide causative information at the pathway level and improve biological
interpretation (Fig. 6.1).
Fig. 1. The flow of carbon atoms from 13C-glucose in metabolism. Carbon-13
atoms from glucose moves through the glycolytic pathway and Krebs cycle while
being part of intermediate molecules. Eventually the Carbon-13 atoms become part
of GSH and other macromolecules. The example shows how isotope-labelled
metabolites can improve biological interpretation in metabolomics.
Source: Lane et al (2011) OMICS. Mar 2011; 15(3): 173–182.
Biological interpretation of metabolites is further dependent on the nature of the
sample. The occurrence of a metabolite in a biofluid (e.g. plasma and urine) would
have a different significance than in a tissue. For example, increased glucose level in
urine would indicate diabetes, whereas increased glucose at the tissue level may not.
In view of this, while databases may provide biological metabolite information for a
certain sample type, the straightforward use of it to other sample types needs to be
cautiously considered. Hence while we may infer biological roles from existing
literature, the context for interpretation should be cautiously factored in.
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6.5 Scalability of experiments
Metabolomics is heavily dependent on statistics to robustly identify changes. This
necessitates sufficient sample size depending on variability of sample and the strength
of the investigated effect. For population or epidemiological studies, a relatively large
sample size is needed to achieve reliable results and this could necessitate scaling up
metabolomics to work with sample sizes of n>100. Technically, it may not be feasible
to run the whole batch of samples within one single analytical batch. This stems from
medium to long-term reproducibility issues of the MS instrument and also downtime
due to preventive maintenance (Dunn et al., 2011).
Fig. 6.2 Scalability of metabolomics to handle large sample sizes. With large
sample size (n>100), more reliable data can be generated but the existing limitations
of medium to long-term instrument reproducibility on a single machine needs to be
addressed. Alternatively the acquisition of data may be performed on multiple
instruments but this gives rise to batch effect. In either cases, robust statistical
corrections may enable the scaling up of analytical runs.
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The samples also unavoidably interact with the chromatographic-MS instrument and
change the response over time in terms of chromatography and MS signals (Dunn et
al., 2011). It is conceivable that to scale up analysis for large samples (n >100), two
approaches could be adopted. The first would involve analysing all samples on one
machine. Over prolonged periods of time, instrument drift would inadvertently distort
data acquisition. The second would be of distributed processing, where samples are
analysed on separate machines and their data recombined for analysis. If such an
approach is adopted, the batch effects may arise. In both strategies, a statistical
framework that can robustly correct drift or combine data from different batches
would be necessary (Fig. 6.2). Projects such as Batch Normalizer (S.-Y. Wang, Kuo,
& Tseng, 2013) & Universal Metabolome-Standard Method (UMS) (Peng, Chen,
Chen, & Li, 2014) have been developing capabilities towards this goal.
Foreseeably in the future, metabolomics would evolve from broad untargeted
profiling towards integrating targeted analysis of metabolites to improve mechanistic
understanding. For biomarker discovery in clinical studies, larger groups of patient
samples are necessary to improve statistical robustness. As the quest for deeper
insights and statistical robustness continues in metabolomics, relevant capabilities
need to be foresighted and planned so we can build them today for the future.
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